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Abstract 
 
Neuroimmune interactions drive chronic itch and inflammation 
 
by 
 
Carolyn M. Walsh 
 
Doctor of Philosophy in Molecular and Cell Biology 
 
University of California, Berkeley 
 
Professor Diana M. Bautista, Chair 
 
 
Chronic itch remains a highly prevalent disorder with limited treatment options. Most 
chronic itch diseases are thought to be driven by both the nervous and immune 
systems, but the fundamental molecular and cellular interactions that trigger the early 
development of itch, and the acute-to-chronic itch transition, remain unknown. Here, we 
show that skin-infiltrating neutrophils are key initiators of itch behaviors in atopic 
dermatitis, the most prevalent chronic itch disorder. Neutrophil depletion significantly 
attenuated itch-evoked scratching behaviors in a mouse model of atopic dermatitis. 
Strikingly, neutrophils were required for several key hallmarks of chronic itch, including 
upregulation of inflammatory cytokines, skin hyperinnervation, enhanced expression of 
itch signaling molecules upregulation of activity-induced genes and markers of 
neuropathic itch in spinal cord and sensory ganglia. We also demonstrate that induction 
of CXCL10, a ligand for the CXCR3 receptor that promotes acute itch via direct 
activation of itch sensory neurons, is neutrophil-dependent. Indeed, we find that 
blockade of CXCR3 signaling attenuates atopic dermatitis itch. Our findings define a 
new role for neutrophils in atopic dermatitis, and establish the importance of CXCR3 
signaling in bridging neutrophils and neurons in the transition from acute to chronic itch. 
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Preface 
 
  
My primary focus during my dissertation research has been, broadly speaking, 
the cellular and molecular mechanisms of chronic itch. Within this topic, I have worked 
specifically on neuroimmune interactions in the context of atopic dermatitis 
pathogenesis. My colleagues and I found that neutrophils are required to trigger the 
development of itch during the first eight days of a mouse model of atopic dermatitis 
(AD), and that these scratching behaviors were further dependent on CXCR3 signaling. 
Another main finding from this research was the surprising discovery that the TSLPR 
signaling pathway, long considered canonical in allergic inflammatory diseases such as 
AD, is not necessary for itch until the second week of the MC903 model despite being 
required for infiltration of basophils and CD4+ T cells to lesional skin. The timing of the 
contributions of the many cell types that drive AD disease is poorly understood, and our 
work makes an important contribution to unraveling this question. Furthermore, the 
discovery that neutrophils play such a key role in the early stages of AD pathogenesis 
has implications for the development of novel therapeutics, particularly since many AD 
patients struggle to control their symptoms with existing treatments. This research 
comprises the second chapter of my dissertation, and is put into context by the first 
chapter, a published book chapter that gives an overview of the field of neuroimmune 
interactions in chronic itch.   
In the last chapter of this dissertation, I offer perspectives and thoughts on future 
directions for my primary thesis work on neuroimmune interactions in atopic dermatitis 
pathogenesis. The highly collaborative nature of my project resulted in a paper with 
multiple fascinating avenues of possible further investigation, and I am grateful to have 
worked with such a talented group of people, each of whom made a unique contribution 
to the work presented in this dissertation.        
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Chapter 1: Introduction to itch and neuroimmune interactions driving chronic itch 
and inflammation.  
 
Previously published as: Walsh CM and Bautista DM. Neuroimmune interactions in 
chronic itch. November 2018. The role of innate immunity in CNS disorders throughout 
the lifespan, chapter. (Garden G, Lipton S, Neumaier J, eds). pp. 31 – 42.  
 
Introduction 
 Chronic itch is a debilitating disorder that affects millions of people worldwide.  Chronic 
itch is driven by cooperative interactions between neurons, epithelial cells and immune 
cells. However, the molecular mechanisms underlying these interactions are not well 
understood.  Here we review the current understanding of the molecular and cellular 
mechanisms in the periphery that drive itch disorders and discuss open questions about 
the neuro-immune interactions that trigger inflammatory itch pathogenesis. 
  
Acute Itch 
Acute itch is an extremely common experience: it can be caused by an insect bite, 
contact with an irritating plant such as poison ivy, or even a wool sweater. While 
unpleasant, the sensation of itch, like pain, is thought to play a fundamental role in 
survival by teaching us to avoid irritating elements in our environment. Itch triggers the 
protective reflex of scratching that promotes removal of irritating plants as well as 
insects and helminths capable of transmitting diseases such as zika or malaria. In 
contrast to acute itch, chronic itch is a profoundly debilitating condition that affects 
roughly 10% of the adult population(Wilson et al., 2013). Chronic itch remains poorly 
understood and difficult to treat, making it a tremendous clinical problem. 
  
Itch is mediated by a subset of somatosensory neurons, a highly heterogeneous group 
of cells that transduce touch, itch, and pain sensations. Somatosensory neurons have 
their cell bodies in the trigeminal and dorsal root ganglia (DRG) and each has a single 
bifurcated axon with one branch innervating the skin and the other innervating the 
dorsal horn of the spinal cord(Carstens et al., 2014).  The peripheral afferents that 
innervate the skin transduce environmental stimuli into electrical signals that travel to 
the central afferent of the neuron and synapse onto a variety of second-order 
interneurons in the spinal cord (Figure 1). 
 
Projection neurons in the spinothalamic tract project from the spinal cord to the 
parabrachial nucleus and the thalamus and activate 3rd order neurons that project to the 
somatosensory cortex. While itch signaling in the central nervous system remains very 
poorly understood, fMRI data reveals that itchy stimuli activate both unique areas and 
some of the pain regions of the primary somatosensory cortex, as well as a myriad of 
brain areas involved in emotional processing, reward, evaluation, and motor 
control(Dong and Dong, 2018). 
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Cells and Molecules of Acute Itch 
Studies have demonstrated two broad classes of itch neurons (termed pruriceptors): 
histamine-dependent and  histamine-independent. While histamine signaling contributes 
to many forms of acute and allergic itch, chronic itch tends to be dominated by non-
histaminergic mechanisms and therefore does not respond to antihistamines. An 
astonishing array of pruritogens leads to activation of distinct subsets of pruriceptors, 
including factors derived from keratinocytes, a wide variety of immune cells, and 
exogenous triggers (Table I). 
 
Recent studies have identified TRPA1 and TRPV1 as two of the primary ion channels 
responsible for driving acute itch excitability. Activation of these channels promotes the 
opening of voltage-gated ion channels that trigger action potential firing and synaptic 
transmission to activate spinal neurons in the dorsal horn. Several molecules have been 
shown to play a key role in itch transmission within the spinal cord including glutamate, 
gastrin-releasing peptide (GRP), natriuretic peptide b (NPPB) and dynorphin(Dong and 
Dong, 2018; Hoon, 2015; Kardon et al., 2014). Glutamate is believed to have a specific 
role in pain signaling and may inhibit itch: genetic deletion of the glutamate transporter, 
VGLUT2, from nociceptive neurons was found to enhance itch behaviors (Dong and 
Dong, 2018). DRG neurons transmit itch signals to second-order spinal cord neurons 
via neuropeptides, including NPPB. NPPB+ DRG neurons synapse onto neurons which 
express the NPPB receptor, NPRA, as well as the neuropeptide GRP. These neurons 
then release GRP onto a group of interneurons in the dorsal horn that express the GRP 
receptor, GRPR(Dong and Dong, 2018). Conversely, some groups have found evidence 
that DRG neurons are able to release GRP directly onto GRPR+ spinal interneurons. 
Itch signaling in the spinal cord is highly complex and is an area of ongoing debate and 
investigation (Figure 2). 
 
Chronic Itch 
While many of the molecules and neurons that drive acute itch have been elucidated in 
the last decade, the molecular and cellular mechanisms that trigger chronic itch remain 
enigmatic. Chronic itch arises from dysfunction of neurons, immune cells, and epithelial 
cells at multiple sites, including the periphery, spinal cord and brain. Psoriasis and 
atopic dermatitis are two of the most prevalent chronic itch disorders. Neuronal and 
immune dysregulation lead to the distinct clinical phenotypes observed in these 
disorders. As such, psoriasis and atopic dermatitis have been the target of 
contemporary studies aimed at defining molecular and cellular mechanisms that 
contribute to disease phenotypes. 
 
Atopic dermatitis is an allergic inflammatory disorder that typically begins in childhood. It 
affects roughly 10-20% of the population worldwide(Bantz et al., 2014). AD is 
characterized by skin barrier dysfunction, thickened lesions and extreme chronic 
itch(Spergel and Paller, 2003). It is believed to be caused by a complex interplay 
between genetic and environmental factors, and is often the first step in a process 
known as the atopic march: children with atopic dermatitis are significantly more likely to 
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develop asthma and allergic rhinitis(Spergel and Paller, 2003). Atopic dermatitis is 
difficult to treat and causes tremendous psychological and financial burdens for the 
patients and families affected. There is an urgent need for a better understanding of the 
pathology of this disorder as well as improved therapies.  
  
Psoriasis is a chronic inflammatory skin disease characterized by defects in 
keratinocyte differentiation, epidermal thickening, and raised scaly plaques on the skin. 
Severe itching is a hallmark symptom of this disorder. It affects 2-3% of the population 
and is considered an “immune centric” disorder, due to the fact that disease clearance 
is observed after immunosuppressive therapies(Golden et al., 2013). The T cell derived 
cytokines IL-17 and IL-23 are believed to be particularly important, and biologic 
therapies that block these cytokines have recently been developed with excellent results 
in patients(Guttman-Yassky and Krueger, 2017).  
 
Until recently, itch research has mainly focused on the roles of epithelial cells and 
immune cells in driving itch and inflammation. However, contrary to the long-held 
viewpoint in which immune cells release mediators that trigger activation in 
somatosensory neurons, leading to chronic itch, a number of contemporary studies 
have demonstrated that both short and long term signaling processes go both ways 
between neurons and immune cells in the periphery. Furthermore, several receptors 
canonically believed to be expressed only in immune cells or neurons have been found 
to play key roles in multiple cell types. These findings demonstrate that an ongoing 
conversation between immune cells and somatosensory neurons is required to drive 
itch and inflammation in the atopic dermatitis disease state. Future therapies will 
depend on furthering our understanding of this conversation. 
 
Immune Cells Modulate Neuronal Function in Chronic Itch 
The direct activation of neurons by immune cells in the context of atopic dermatitis 
remains an important avenue whereby itch and inflammation are induced. In addition to 
simply activating neurons, immune cells change the signaling behavior of 
somatosensory neurons in a number of complex ways, including lowering excitation 
thresholds, evoking neurite outgrowth, and facilitating immune cell-neuron contacts in 
the periphery. Four immune cell types have been shown to directly influence neuronal 
excitability, sensitization and branching in the context of chronic itch: Langerhans cells, 
T cells, eosinophils and mast cells (Figure 3). A consistent theme in the story of immune 
cell signaling to neurons is the neuronal expression of receptors long believed to 
function only in immune cells, including, a variety of canonical immune cell receptors, 
e.g. IL-31Rɑ, IL-4Rɑ, IL-13Rɑ1 (Table I), among others, are expressed and active on 
somatosensory neurons, as described below.  
  
Langerhans cells are dendritic cells located in the epidermis and are important in 
initiating cutaneous immune responses. Their dendritic processes are located in the 
stratum corneum, the most superficial layer of the skin, and promote skin barrier 
homeostasis(Jaitley and Saraswathi, 2012; Seneschal et al., 2012; Yoshida et al., 
	 4 
2014). Like other types of dendritic cells, Langerhans cells respond to antigens from the 
external and internal environment and upon activation, influence T cell activation and 
migration(Ding et al., 2008). A role for Langerhans cells in atopic dermatitis comes from 
both human and animal studies. Human atopic skin contains significantly higher 
numbers of Langerhans cells and they display an altered morphology, with more 
dendritic branches that extend through tight junctions towards the superficial epidermis. 
These branches have the molecules that capture exogenous antigens, including 
haptens or viral antigens. These antigens are presented to T cells, triggering 
activation(Dubrac et al., 2010; Nakajima et al., 2012). Cultured murine Langerhans cells 
produce nitric oxide in response to the potent inflammatory agents lipopolysaccaride 
and interferon-gamma(Qureshi et al., 1996). Nitric oxide is a well-known agonist of  the 
TRPA1 and TRPV1 ion channels, which have been shown to play key roles in many 
forms of acute and  chronic itch(Bautista et al., 2014; Kittaka and Tominaga, 2017). 
Furthermore, one study(Morita et al., 1995) showed decreases in pruritis among atopic 
dermatitis patients in response to a topical nitric oxide synthase inhibitor, suggesting a 
role for this molecule in AD pathogenesis. More direct evidence for a role of Langerhans 
cells comes from mouse models of AD, in which depletion of Langerhans cells 
significantly decreases skin inflammation and lesions(Elentner et al., 2009).  
 
T cells play a key role in atopic dermatitis. While T cells have long been known to 
communicate with other immune cells and epithelial cells, their interactions with 
somatosensory neurons under chronic itch conditions were unknown until recently. 
There are multiple kinds of T cells, including cytotoxic T cells, which kill cells that are 
infected with bacteria or viruses, and helper T cells, which secrete cytokines that then 
act on other types of cells. Helper T cells are further specialized into subtypes, such as 
Th1, Th2, Th17, etc., depending on their mode of activation  (e.g., viral or bacterial 
infection, allergen exposure, etc.). The Th17 subtype of T cells is a key mediator of 
psoriasis(Guttman-Yassky and Krueger, 2017). Th17 cells secrete a variety of 
inflammatory interleukins which in turn alter the activity of many genes involved in skin 
barrier function that trigger psoriatic phenotype. In contrast, the Th2 subtype of T cells is 
activated in essentially all atopic dermatitis patients, while Th17 and Th1 activation is 
additionally seen only in a subset of patients(Guttman-Yassky and Krueger, 2017).  
Cyclosporine is a potent immunosuppressant that acts to inhibit T-cells by inhibiting 
signal transduction downstream of  T Cell Receptor activation. Cyclosporine very 
effectively suppresses the atopic dermatitis disease phenotype short-term(Khattri et al., 
2014), but due to relapse and renal toxicity, is not an effective long-term therapy.  
 
IL-31, a cytokine largely derived from Th2 cells, is highly upregulated in atopic 
dermatitis patients(Nobbe et al., 2012). Cevikbas and colleagues discovered that IL-31 
evokes calcium transients in cultured DRG neurons and triggers itch in mice upon 
injection into the skin(Cevikbas et al., 2014). These results were dependent upon the 
ion channels TRPV1 and TRPA1, which play key roles in immune cell function. 
Moreover, IL-31 has been implicated in neurite outgrowth(Feld et al., 2016). Increases 
in nerve fiber density are observed in the skin of AD patients, likely contributing to their 
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itch and inflammation symptoms(Tominaga and Takamori, 2014). Indeed, 
overexpression of  IL-31 in lymphocytes or intradermal injection of the protein in mice 
triggers dramatic sprouting of sensory nerve fibers in the skin(Feld et al., 2016).  
 
In addition to Th2 cells, eosinophils are also thought to be key regulators of sensory 
neuron innervation in chronic itch. Eosinophils are a type of white blood cell granulocyte 
that mediate viral, bacterial and fungal defense and immunoregulation(Radonjic-Hösli 
and Simon, 2014; Simon et al., 2004).  In atopic dermatitis patients, eosinophil counts 
and eosinophil granule proteins are elevated in peripheral blood, and correlate with 
disease severity(Simon et al., 2004). The number of eosinophils is also increased in the 
skin in multiple chronic itch mouse models(Foster et al., 2011; Li et al., 2006). A recent 
study demonstrated that eosinophils contribute to skin barrier dysfunction in a mouse 
model of atopic dermatitis(Naidoo et al., 2018), underscoring the importance of these 
cells in AD pathology. Eosinophils have been recently demonstrated to increase 
somatosensory neurite branching in mouse neuron-eosinophil co-cultures, and when 
sensory neurons were treated with medium from these co-cultures. These results 
suggest that the close functional interaction between eosinophils and neurons is 
necessary for full eosinophil-mediated increase in neurite branching(Foster et al., 2011). 
Whether such interactions drive hyperinnervation in atopic dermatitis in vivo has yet to 
be directly examined. While psoriatic lesions also display hyperinnervation(Taneda et 
al., 2011), it is unclear whether eosinophils and/or T cells contribute to this phenotype.  
 
Mast cells are tissue-resident granulocytes that contribute to inflammatory chronic itch 
via degranulation and release of inflammatory cytokines. In human atopic dermatitis, 
mast cells are more abundant in lesional skin and display a high prevalence of 
degranulation(Liu et al., 2011). A number of studies have shown that mast cells can 
both directly activate and sensitize somatosensory neurons in the skin. The products of 
mast cell degranulation,  including serotonin, histamine, Bam8-22, and proteases, 
potently and directly activate their cognate receptors on somatosensory neurons to 
drive itch behaviors and to promote neurogenic inflammation via the release of  
inflammatory peptides. Mast cell-neuron interactions have been shown to be 
strengthened in a mouse model of atopic dermatitis. Hagiyama et. al. demonstrated that 
mast cells upregulate expression of intercellular adhesion molecule 1 (ICAM-1), which 
mediates mast cell-sensory neuron interactions(Hagiyama et al., 2013). These data 
suggest that the strengthening of mast-cell neuronal interactions may contribute to the  
increased degranulation and neuronal activation observed in atopic dermatitis. 
 
Mast cells may also regulate the expression of excitatory signaling molecules within 
sensory neurons, thereby promoting hyperexcitability. Expression of the ion channel 
TRPA1 is markedly increased in skin biopsies from atopic dermatitis patients as 
compared to normal skin, and also in the IL-13 mouse model of atopic dermatitis(Oh et 
al., 2013). TRPA1 is also required for itch behaviors in multiple mouse models of atopic 
dermatitis(Morita et al., 2015; Oh et al., 2013).  Interestingly, mast cell deficient mice do 
not display the increased expression of TRPA1 in lesional skin. IL-13 also directly 
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activates and sensitizes DRG neurons and increases itch-evoked scratching behaviors 
in mice following injection of a variety of  pruritogens(Oetjen et al., 2017). This cytokine 
is released by both Th2 cells and mast cells, though the relative contributions of mast 
cells vs Th2 derived IL-13 to neuronal excitation is unknown. 
 
Neurons Recruit and Activate Immune Cells in Chronic Itch  
Far from being passive recipients of messages from immune cells, neurons actively 
participate in driving inflammation in a variety of chronic itch disorders (Figure 4). 
Psoriasis provides an excellent example of this phenomenon: it has long been 
understood as an “immune-centric” disease, driven by the action of Th17 helper cells. 
However, multiple lines of evidence support the requirement for neuronal signaling in 
this disorder, highlighting the complex, multicellular nature of the disease.  
 
Psoriatic plaques have a high expression of neuropeptides and are hyper-innervated by 
somatosensory neurons(Ostrowski et al., 2011). Clinically, spontaneous remission of 
psoriasis plaques have been reported in patients following nerve injury, and two pilot 
studies have demonstrated that injections of botulinum toxin have beneficial effects in 
psoriasis patients(Campanati et al., 2017; Ward et al., 2012).  These clinical 
observations were recently recapitulated in the lab: treatment with botulinum toxin 
ameliorated psoriasis-like symptoms in the KC-Tie2 genetic mouse model of 
psoriasis(Ward et al., 2012), which displays the immunological, epithelial and neural 
characteristics of human disease. Surgical cutaneous denervation in this model results 
in significant reductions in epidermal thickening and T cell infiltrate. These deficits could 
be rescued by intradermal injection of calcitonin gene related peptide (CGRP), a potent 
vasodilatory and inflammatory neuropeptide produced by somatosensory nerves or by 
activating the receptor for substance P (SP), another inflammatory neuropeptide, with a 
selective agonist(Ostrowski et al., 2011). These data suggest that in addition to T cells, 
neuropeptide signaling from sensory neurons drives epithelial cell dysfunction and 
inflammation in psoriasis.  
 
Moreover, recent studies have begun to explore the role played by somatosensory 
neurons in atopic dermatitis pathogenesis. Neurons signal to and regulate multiple 
types of immune cells in AD. Indeed, inflammatory neuropeptide release by 
somatosensory neurons has been shown to dramatically influence Langerhans cell 
activity. Langerhans cells play a key role in driving the Th2 response in AD. In a series 
of in vitro experiments, Ding et. al. demonstrated that treating cultured Langerhans cells 
from mouse epidermis with CGRP upregulated their expression of Th2 cytokines. 
Furthermore, CD4+ T cells to which these CGRP-treated Langerhans cells presented 
antigens demonstrated Th2-type polarization(Ding et al., 2008). This work indicates that 
somatosensory neuronal signaling actually promotes a Th2 response, which is central 
to the pathology of AD.  
 
Eosinophils, noted above for their remarkable ability to evoke neurite outgrowth, also 
respond to neuronal signaling. Cultured DRG neurons produce the potent and specific 
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eosinophil chemokine, eotaxin-1, as well as the adhesion molecules ICAM-1 and 
VCAM-1(Foster et al., 2011). ICAM-1 functions as a ligand for LFA-1, while VCAM-1 
binds to VLA-4. Both VLA-4 and LFA-1 are expressed by eosinophils(Lima et al., 2007). 
Moreover, eotaxin levels are elevated in atopic dermatitis lesions(Owczarek et al., 
2010). These data suggest that under atopic dermatitis conditions, neurons call 
eosinophils to lesions and eosinophils promote additional neuronal sprouting. Clearly, 
understanding neuron-eosinophil bidirectional signaling is fundamental to increasing our 
knowledge of these enigmatic cells.  
 
Somatosensory nerve endings have been shown to be in close proximity to mast cells in 
both chronic itch and pain. Previous work has established that neuron-mast cell 
interactions are required for pain hypersensitivity(Chatterjea and Martinov, 2015). 
Somatosensory neurons secrete the metalloprotease MT5-MMP which can trigger mast 
cell degranulation and regulate neuron-mast cell contact via N-cadherin(Folgueras et 
al., 2009). Mice lacking this protease display alterations in chronic pain(Folgueras et al., 
2009), but chronic itch has not yet been examined in these animals. Within the field of 
chronic itch, neuronal-mast cell interactions are proving to be equally crucial.  
 
Substance P is an inflammatory neuropeptide released by somatosensory neurons 
implicated in both chronic itch and pain(Azimi et al., 2017; Chiu et al., 2012). Substance 
P acts as a robust pruritogen in both humans and rodents. Interestingly, inhibition of the 
canonical substance P receptor, neurokinin-1 receptor (NK-1R), has no effect on 
substance P evoked scratching(Azimi et al., 2017). Recent studies have identified a 
member of  the Mas-related g-protein coupled receptor (Mrgpr) family, MrgprB2, as a 
new target for substance P. Indeed, substance P-evoked itch behaviors are inhibited by 
MrgprB2 antagonists in both wild-type and NK-1R knockout animals(Azimi et al., 2016).  
 
While the Mrgpr family is well-known for mediating neuronal responses to 
pruritogens(Liu and Dong, 2015), MrgprB2 is exclusively expressed on mast cells. 
Recent studies have shown that MrgprB2 is required for mast cell activation by a variety 
of secretagogues, including substance P(McNeil et al., 2014). In fact, substance P does 
not evoke degranulation in cells transfected with missense mutants in the human 
orthologue of MrgprB2, MRGPRX2(Alkanfari et al., 2018). These finding highlight a key 
role for neurons in regulating mast cell function. 
 
Beyond the Periphery 
While interactions between neurons and immune cells in the skin are clearly 
fundamental to the development of chronic itch and pain, neuroimmune signaling in the 
CNS also plays a key role(Romero-Sandoval et al., 2008). Indeed, persistent activation 
of microglia in the CNS is believed to drive the persistence of chronic pain, suggesting 
that glial cells in the CNS may also contribute to chronic itch pathogenesis(Hulsebosch, 
2012). While microglia have not been examined in atopic dermatitis or psoriasis mouse 
models, they may play a key role in a contact hypersensitivity model of chronic itch, 
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DNFB (Zhang et al., 2015). This is sure to be an active area of research moving 
forward. 
 
 Another recent study focused on the contribution of reactive astrogliosis, a change in 
the morphology of spinal astrocytes resulting in increased arborization and enlarged cell 
bodies, to chronic itch. Astrogliosis and expression of the astrocytic marker GFAP was 
recently demonstrated  in the dorsal spinal cord in a mouse model of atopic 
dermatitis(Shiratori-Hayashi et al., 2015). This was dependent on TRPV1-expressing 
peripheral itch fibers that innervate the dorsal horn, and observed in areas of the spinal 
cord that connect to scratched areas of the skin. Furthermore, scratching behaviors and 
astrogliosis were partially dependent on the astrocyte transcription factor STAT3. 
Perhaps most intriguing, while STAT3 knockout animals displayed reduced chronic 
scratching behavior, their acute itch responses remained intact, suggesting that this 
transcription factor plays a key role in the transition to a chronic itch state. LCN2, a 
protein involved in intracellular transport, was also identified as a possible downstream 
target of STAT3 responsible for mediating its effects(Shiratori-Hayashi et al., 2015). The 
mechanisms by which changes in spinal and central signaling mediate the development 
of chronic itch remain a fascinating and active area of ongoing research.  
 
Conclusion 
A great deal of progress has been made in understanding the 
neuroimmune mechanisms of chronic itch in recent years. However, a number of open 
questions remain: What are the relative contributions of neurons and immune cells to 
chronic itch pathophysiology?  Some of the same cell types implicated in chronic itch 
are also linked to chronic pain. What makes these cells behave differently in one 
disease context versus another? Are the neuroimmune signaling pathways in atopic 
dermatitis and psoriasis conserved in other inflammatory itch conditions? Will effective 
therapeutics require the blockade of both neuronal and immune cell pathways? 
  
While early therapeutics, such as cyclosporine and steroids, have focused on broad 
immunosuppression, incomplete itch relief, remission, lack of penetrance, toxicity and 
side effects make these types of treatments poor options for long term use. A number of 
particularly exciting recent advances have been made in the area of biologics, which 
block the actions of key cytokines that drive chronic itch pathology. Recent studies have 
shown that IL-17 or IL-23 targeting antibodies are effective in reducing symptoms in  
psoriasis patients(Guttman-Yassky and Krueger, 2017). Although antibody targeting has 
thus far proven less successful for atopic disease (Sheridan, 2018), early studies show 
that dupilimab, which inhibits both IL-4 and IL-13 signaling by blocking IL4Ra, looks 
quite promising for treating medium to severe atopic dermatitis(Simpson et al., 2016). 
Perhaps the effectiveness of these treatments stems from their abilities to inhibit 
signaling in both immune and neuronal cell types. The groundbreaking work now being 
done in the neuroimmune interactions driving chronic itch is sure to provide crucial 
insights that pave the way for new therapies. 
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Figure 1. Somatosensory neurons have cell bodies in the dorsal root ganglia (DRG). 
These neurons are pseudounipolar and have two axonal branches: one branch 
innervates the epidermis, where environmental stimuli are transduced into action 
potentials, the other innervates interneurons in the dorsal horn of the spinal cord, where 
the signals are processed and sent to the brain. Somatosensory neurons are diverse, 
with itch and pain neurons innervating the epidermis and dermis and interacting with 
immune cells in multiple layers of the skin. 
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Figure 2. Itch processing the spinal cord is highly complex. Several molecules that play 
key roles in itch transmission in the spinal cord have been identified, including 
glutamate, gastrin-releasing peptide (GRP), gastrin-releasing peptide receptor (GRPR), 
and dynorphin.  Schematic depicts a hypothetical schematic of circuits based on the 
current literature. Triangular and rectangular synaptic symbols indicate excitatory and 
inhibitory connections. Primary somatosensory neurons in the DRG can be categorized 
by their gene-expression profiles. Single-cell expression profiling revealed 3 subtypes of 
itch neurons termed NP1, NP2, and NP3. NP1 neurons are characterized by their 
expression of MrgprD, NP2 by MrgprA3, and NP3 by serotonin receptors. The MrgprA3+ 
NP2 neurons have been shown to be itch-specific neurons since activating these 
neurons elicit only itch behaviors. Itch sensory neurons make synaptic connections with 
GRP+ interneurons in the spinal cord, which are in turn connected with GRPR+ neurons. 
Ablation of GRPR signaling or GRPR+ neurons completely abolished responses to itchy 
stimuli, indicating vital importance of this pathway in itch transmission. Information about 
itch stimuli in the periphery is eventually conveyed to higher brain centers by projection 
neurons. The parabrachial nucleus (PBN) in the brainstem serves as an important relay 
center in the process. Itch interacts with other sensory modalities in the spinal cord. 
GRP+ neurons receive both itch and pain stimuli but will inhibit their own responses to 
high-intensity pain sensation through enkephalin signaling. Meanwhile, a painful 
stimulus will activate both itch and pain sensory neurons. But only pain will be perceived 
because itch is inhibited by pain via inhibitory interneurons in the spinal cord. One group 
of these interneurons is marked by the transcription factor BHLHB5. These neurons are 
activated by a variety of anti-itch stimuli and likely inhibit itch via the release of 
dynorphin and glycine. Similarly, a group of inhibitory interneurons labeled by the NPY 
neuropeptide were shown to mediate the inhibition of mechanical itch by light touch, 
though the sensory neurons and further transduction circuits of mechanical itch remain 
to be identified. The spinal cord dorsal horn also receives descending neuromodulation 
from higher brain centers. The raphe magnus (NRM) sends serotoninergic projections 
to the spinal cord and can stimulate GRPR+ neurons and potentiate itch by co-activating 
HTR1A and GRPR receptors. The dorsal horn also receives tonic noradrenergic 
inhibition, likely from the locus coeruleus (LC). GRPR+ neurons in the suprachiasmatic 
nucleus (SCN) of the hypothalamus have been suggested to play a role in contagious 
itch. 
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Figure 3. Immune cells modify neuronal activity to promote chronic itch. Langerhans 
cells, Th2-type CD4+ T cells, mast cells, and eosinophils have been shown to modulate 
neuronal function chronic itch disorders.  
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Figure 4. Neurons act on numerous immune cells to modulate their activity in chronic 
itch disorders, including Langerhans cells, mast cells and eosinophils. 
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Table I. A remarkable variety of pruritogens derived from epithelial cells, immune cells, 
and the environment activate somatsoesensory neurons and evoke itch sensations and 
scratching behaviors.  
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Chapter 2: Neutrophils promote CXCR3-dependent itch in the development of 
atopic dermatitis 
 
Previously published as: Walsh CM, Hill RZ, Schwendinger-Schreck J, Deguine J, 
Brock EC, Kucirek N, Rifi Z, Wei J, Gronert K, Brem R, Barton GM, Bautista DM. 
Neutrophils promote CXCR3-dependent itch in the development of atopic dermatitis. 
BioRxiv. 2019 May, doi: https://doi.org/10.1101/653873. 
 
 
INTRODUCTION 
  
Chronic itch is a debilitating disorder that affects millions of people worldwide (Dalgard 
et al., 2015; Matterne et al., 2011; Mollanazar et al., 2016). It is a symptom of a number 
of skin diseases and systemic disorders, as well as a side effect of a growing list of 
medications. Like chronic pain, chronic itch can also be a disease in and of itself 
(Berger et al., 2013; Stumpf and Ständer, 2013). Unlike acute itch, which can facilitate 
removal of crawling insects, parasites, or irritants, persistent scratching in chronic itch 
disorders damages skin, leading to secondary infection, disfiguring lesions, and 
exacerbation of disease severity (Mack and Kim, 2018; Yosipovitch and Bernhard, 
2013). One of the most common chronic itch disorders is atopic dermatitis (AD; 
commonly known as eczema), which affects fifteen million people in the US alone. 
Severe AD often leads to the atopic march, where chronic itch and inflammation 
progress to food allergy, allergic rhinitis, and asthma. 
 
Little is known about the underlying mechanisms that drive chronic itch pathogenesis. 
As such, studies of human chronic itch disorders have sought to identify candidate 
mechanisms of disease progression. A number of studies have identified biomarkers 
and disease genes in human atopic dermatitis (AD) itch lesions (BS et al., 2012; Ewald 
et al., 2017; Guttman-Yassky et al., 2009; Jabbari et al., 2012; Li et al., 2014; Suárez-
Fariñas et al., 2015). Indeed, a recent study compared the transcriptomes of healthy 
skin to itchy and non-itchy skin from psoriasis and AD patients, revealing dramatic 
changes in expression of genes associated with cytokines, immune cells, epithelial 
cells, and sensory neurons (Nattkemper et al., 2018). However, due to the difficulty in 
staging lesion development and obtaining staged samples from patients, there is 
currently no temporal map of when individual molecules and cell types contribute to 
chronic itch pathogenesis. Furthermore, the use of human patient data does not allow 
for rigorous mechanistic study of how disease genes contribute to chronic itch. To this 
end, we used a well-characterized inducible animal model of itch to define where, when, 
and how these genes identified from patient data contribute to chronic itch 
pathogenesis.  
 
We employed the MC903 mouse model of AD and the atopic march (Dai et al., 2017; Li 
et al., 2009a; 2006; Moosbrugger-Martinz et al., 2017; Zhang et al., 2009) to provide a 
framework in which to identify the molecules and cells that initiate the development of 
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atopic itch. The MC903 model is ideal for this approach because of its well-defined time 
course of lesion development and scratching onset (Li et al., 2006; Morita et al., 2015; 
Oetjen et al., 2017; Zhang et al., 2009). While MC903 has been widely used to study 
the chronic phase of AD (Kim et al., 2013; 2014; Li et al., 2006; 2009b; Naidoo et al., 
2018; Oetjen et al., 2017; Zhang et al., 2009), we hypothesized that MC903 could also 
be used to define the early mechanisms underlying the development of chronic itch, 
beginning with healthy skin. We performed RNA-seq of skin at key time points in the 
model and complemented this approach with measurements of itch behavior and 
immune cell infiltration. The primary goal of our study was to identify the inciting 
molecules and cell types driving development of chronic itch. To that end we found that 
infiltration of neutrophils into skin is required for development of chronic itch behaviors. 
Additionally, we demonstrate that early hyperinnervation of skin, and upregulation of itch 
signaling molecules and activity-induced genes in neurons are also dependent on 
neutrophils. Finally, we identify CXCL10/CXCR3 signaling as a key link between 
infiltrating neutrophils and sensory neurons that drives itch behaviors.  
 
 
RESULTS 
 
MC903 triggers rapid changes in expression of skin barrier, epithelial cell-derived 
cytokine, and axon guidance genes 
Although a variety of AD- and chronic itch-associated genes have been identified, when 
and how they contribute to disease pathogenesis is unclear. Using RNA-seq of MC903-
treated skin, we observed distinct temporal patterns by which these classes of genes 
were differentially expressed across the first eight days of the model (Figure 1A-B, 
Figure 1-Figure Supplement 1A). Proteases (Klk6, Klk13, among others) and skin 
barrier genes (Cdhr1) changed as early as six hours after the first treatment, before 
mice begin scratching (Figure 1A).  Increased protease activity in AD skin is thought to 
promote breakdown of the epidermal barrier and release of inflammatory cytokines from 
keratinocytes (Steinhoff et al., 2003; Yosipovitch, 2004). One such cytokine, thymic 
stromal lymphopoetin (TSLP) is a key inducer of the Type 2 immune response, which is 
characteristic of human AD and the MC903 model, via signaling in CD4+ T cells, 
basophils, and other immune cells (Briot et al., 2009; Demehri et al., 2009; Gao et al., 
2010; Kim et al., 2013; Li et al., 2009a; Zhang et al., 2009). Beginning at day two, 
before any significant itch-evoked scratching (Figure 1A), immune cell infiltration (Figure 
1E-G, Figure 1-Figure Supplement 2A-C), or skin lesions (data not shown) were 
observed, we saw increases in Tslp, as well as several other epithelial-derived 
cytokines, including the neutrophil chemoattractant genes Cxcl1, Cxcl2, Cxcl3, and 
Cxcl5 (Figure 1D). To ask whether upregulation of these chemokine genes was 
dependent on protease activity, we treated human keratinocytes with the Protease 
Activated Receptor 2 agonist SLIGRL. SLIGRL treatment triggered increased 
expression of several of these chemokine genes, including IL-8, the human ortholog of 
mouse Cxcl1/Cxcl2, and CXCL2 (Figure 1-Figure Supplement 3A). These increases 
occurred after a few hours of exposure to SLIGRL, suggesting that increased protease 
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activity can rapidly trigger increases in neutrophil chemokines in skin, similar to what we 
observe in MC903-treated mouse skin. 
 
Unexpectedly, we observed early changes in a number of transcripts encoding neuronal 
outgrowth factors (Ngf, Artn) and axon pathfinding molecules (Slit1, Sema3d, Sema3a), 
some of which are directly implicated in chronic itch (Hidaka et al., 2016; Kou et al., 
2012; Tominaga et al., 2008; Tominaga and Takamori, 2014); Figure 1-Figure 
Supplement 4A), prior to when mice began scratching. We thus used 
immunohistochemistry (IHC) of whole-mount skin to examine skin innervation at this 
time point. We saw increased innervation of lesions at day two but not day one of the 
model (Figure 1H-I, Figure 1-Figure Supplement 5A). This increase came as a surprise 
because such changes had previously only been reported in mature lesions from 
human chronic itch patients (Haas et al., 2010; Kamo et al., 2013; Nattkemper et al., 
2018; Oaklander and Siegel, 2005; Pereira et al., 2016; Schüttenhelm et al., 2015; 
Tominaga et al., 2009). Our findings suggest that early hyperinnervation is promoted by 
local signaling in the skin and is independent of the itch-scratch cycle. 
 
Neutrophils are the first immune cells to infiltrate AD skin 
At day five, mice exhibited robust itch behaviors and stark changes in a number of AD 
disease genes (Figure 1A-B). For example, loss-of-function mutations in filaggrin (FLG) 
are a major risk factor for human eczema (Palmer et al., 2006). Interestingly, Flg2 levels 
sharply decreased by this time point. In parallel, we saw a continued and significant 
elevation in neutrophil and basophil chemoattractant genes (Cxcl1,2,3,5, and Tslp, 
Figure 1D).  Using flow cytometry, we determined that neutrophils were the most highly 
increased cell type in the skin at day five (Figure 1E). It was not until day eight that we 
observed the classical AD-associated immune signature (Gittler et al., 2012) in the skin, 
with upregulation of Il4, Il33 and other Th2-associated genes (Figure 1B, Figure 1D). 
We also observed increases in the T cell chemoattractants Cxcl9, Cxcl10, and Cxcl11 
(Figure 1D), which are thought to be hallmarks of chronic AD lesions in humans 
(Mansouri and Guttman-Yassky, 2015; Oetjen and Kim, 2018). Neutrophils and a 
number of other immune cells that started to infiltrate on day five were significantly 
elevated in skin by day eight, including basophils (Figure 1F), CD4+ T cells (Figure 1G), 
inflammatory monocytes (Figure 1-Figure Supplement 2A), and mast cells (Figure 1-
Figure Supplement 2B), but not eosinophils (Figure 1-Figure Supplement 2C).  
 
CD4+ T cells are ubiquitous in human AD lesions (Guttman-Yassky and Krueger, 2017) 
and have been shown to play a key role in promoting chronic AD itch and inflammation 
(Oetjen et al., 2017). More specifically, they are implicated in IL4Rα-dependent 
sensitization of pruriceptors in the second week of the MC903 model (Oetjen et al., 
2017). Thus, we were quite surprised to find that itch behaviors preceded significant 
CD4+ T cell infiltration. Therefore, neutrophils drew our attention as potential early 
mediators of MC903 itch. While neutrophil infiltration is a hallmark of acute 
inflammation, it remains unclear whether neutrophils contribute to the pathogenesis of 
chronic itch. Moreover, neutrophils release known pruritogens, including proteases 
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and/or histamine, and secrete inflammatory lipids and cytokines that sensitize and/or 
activate pruriceptors (Dong and Dong, 2018; Hashimoto et al., 2018). Increased levels 
of PGE2 and the neutrophil-specific lipid LTB4 have also been reported in skin of AD 
patients (Fogh et al., 1989). Indeed, by mass spectrometry, we observed increases in 
several of these inflammatory lipids, PGD2 and PGE2, as well as LTB4 and its precursor 
5-HETE (Figure 1-Figure Supplement 6A). Thus, we next tested the requirement of 
neutrophils to itch in the MC903 model. 
 
Neutrophils are required for early itch behaviors in the MC903 model of AD 
We first asked whether neutrophils were required for MC903-evoked itch by depleting 
neutrophils, the earliest and largest population of infiltrating immune cells in this chronic 
itch model. Depletion of neutrophils by daily injections of an anti-Gr1 (aGr1) antibody 
(Ghasemlou et al., 2015; Kim et al., 2009; Sivick et al., 2014) dramatically attenuated 
itch-evoked scratching through the first eight days of the model (Figure 2A). Consistent 
with a key role for neutrophils in driving chronic itch, our depletion strategy significantly 
and selectively reduced circulating and skin infiltrating neutrophils on days five and 
eight, days on which control, but not depleted mice, scratched robustly (Figure 2B; 
Figure Supplement 1A-C). In contrast, basophils and CD4+ T cells continued to infiltrate 
the skin following aGr1 treatment (Figure 2C-D), suggesting that these cells are not 
required for early MC903 itch. 
 
We next used the cheek model of acute itch (Shimada and LaMotte, 2008) to ask 
whether neutrophil recruitment is sufficient to trigger itch. As expected, we observed 
significant and selective recruitment of neutrophils to cheek skin within 15 minutes after 
CXCL1 injection (Figure 2-Figure Supplement 2A-B). CXCL1 injection also triggered 
robust scratching behaviors (Figure 2E) on a similar time course to neutrophil infiltration 
(Figure 2 - Figure Supplement 2B). Thus, we depleted neutrophils with aGr1 to 
determine whether neutrophils were required for CXCL1-evoked acute itch. Indeed, 
aGr1-treatment resulted in a dramatic loss of CXCL1-evoked itch behaviors (Figure 2C). 
This effect was specific to neutrophil-induced itch as injection of chloroquine, a 
pruritogen that directly activates sensory neurons, triggered robust scratching in aGr1-
treated animals (Figure 2-Figure Supplement 3A). Given that CXCL1 has been shown 
to directly excite and/or sensitize sensory neurons (Deftu 2017,2018), it is possible that 
the CXCL1 mechanism in itch may also involve neuronal pathways. However, our 
results show that CXCL1-mediated neutrophil infiltration is sufficient to drive acute itch 
behaviors, and that neutrophils are necessary for itch in the MC903 model. 
 
We also examined the MC903-evoked itch behaviors of mice deficient in Crlf2, the gene 
encoding the TSLP receptor (TSLPR-/- mice; (Carpino et al., 2004). TSLPR is expressed 
by both immune cells and sensory neurons and is a key mediator of atopic dermatitis in 
human and mouse models. Surprisingly, MC903-treated TSLPR-/- mice displayed robust 
scratching behaviors during the first eight days of the model (Figure 2F). In contrast to 
our results in aGR1-injected mice, TSLPR-/- mice displayed robust neutrophil infiltration 
(Figure 2G), but a complete loss of basophil and CD4+ T cell infiltration into the skin 
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(Figure 2H-I). These results suggest that basophils and T cells are not required for early 
itch and further support an inciting role for neutrophils. Previous studies have shown 
that TSLP drives the expression of Type 2 cytokines and related immune cells that 
promote itch and inflammation in mature AD skin lesions and in the second week of the 
MC903 AD model (Briot et al., 2009; Demehri et al., 2009; Li et al., 2009a; Zhang et al., 
2009). Consistent with a later stage role for TSLP signaling in AD, we did observe a 
significant reduction in itch-evoked scratching in TSLPR-/- mice in the second week of 
the model (Figure 2F). Thus, our data support a model in which neutrophils are 
necessary for initiation of AD and itch behaviors early in the development of AD, while 
TSLPR signaling mediates the recruitment of basophils and CD4+ T cells to promote 
later stage itch and chronic inflammation. 
 
MC903 drives rapid and robust changes in the peripheral and central nervous 
systems 
But how do neutrophils drive MC903 itch? Itchy stimuli are detected and transduced by 
specialized subsets of peripheral somatosensory neurons. Thus, to answer this 
question we first profiled the transcriptional changes in somatosensory neurons in the 
MC903 model, which were previously unstudied. In general, little is known regarding 
neuronal changes in chronic itch. Our initial examination of early hyperinnervation and 
changes in axon guidance molecules in skin suggested that neurons are indeed 
affected early on in the MC903 model, before the onset of itch-evoked scratching 
behaviors. In contrast to the skin, where we saw many early transcriptional changes, we 
did not see any significant transcriptional changes in the trigeminal ganglia (TG) until 
five days after the first treatment, and in total only 84 genes were differentially 
expressed through the eighth day (Figure 3A-B). These hits included genes related to 
excitability of itch sensory neurons (Dong and Dong, 2018; Usoskin et al., 2015), 
neuroinflammatory genes (Takeda et al., 2009) and activity-induced or immediate early 
genes (Figure 3A). Interestingly, we observed enrichment of neuronal markers 
expressed by one specific subset of somatosensory neurons that are dedicated to itch 
(Il31ra, Osmr, Trpa1, Cysltr2, and Nppb (Solinski et al., 2019; Usoskin et al., 2015), 
termed “NP3” neurons. Similar to what has been reported in mouse models of chronic 
pain, we observed changes in neuroinflammatory (Bdnf, Nptx1, Nptx2, Nptxr) and 
immune genes (Itk, Cd19, Rag, Tmem173). However, these transcriptional changes 
occurred just a few days after itch onset, in contrast to the slow changes in nerve injury 
and pain models that occur over weeks (Scholz and Woolf, 2007), indicating that 
neuropathic changes may occur sooner than previously thought. These changes 
occurred in tandem with the onset of scratching behaviors (Figure 1C), suggesting that 
the early molecular and cellular changes we observed by this time point may be 
important for development of itch-evoked scratching. 
 
The changes we observed in immune-related genes in the TG were suggestive of 
infiltration or expansion of immune cell populations, which has been reported in models 
of nerve injury and chronic pain, but has never been reported in chronic itch. To validate 
our observations, we used IHC to ask whether CD45+ immune cells increase in the TG. 
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We observed a significant increase in immune cell counts at day eight but not day five 
(Figure 3C-F, Figure 3-Figure Supplement 1A-D). Because we observed such dramatic 
expression changes in the TG on day eight of the model, we postulated that the CNS 
may also be affected at this time point. Thus, we performed RNA-seq on spinal cord 
segments that innervate the rostral back skin of MC903-treated mice. To date, only one 
study has examined changes in the spinal cord during chronic itch. They showed that 
upregulation of the STAT3-dependent gene Lcn2 occurred three weeks after induction 
of chronic itch and was essential for sustained scratching behaviors (Shiratori-Hayashi 
et al., 2015). Surprisingly, we saw upregulation of Lcn2 on day eight of the MC903 
model and, additionally, we observed robust upregulation of immediate early genes 
(Fos, Junb, Figure 3G), suggesting that MC903 itch drives activity-dependent changes 
in the spinal cord as early as one week after beginning treatment. Together our findings 
show that sustained itch and inflammation can drive changes in the PNS and CNS 
much sooner than previously thought, within days rather than weeks after the onset of 
scratching. We next set out to ask how loss of neutrophils impacted the molecular 
changes observed in skin and sensory neurons in the MC903 model, and which of 
these changes might contribute to neutrophil-dependent itch. 
 
Neutrophils are required for upregulation of select itch- and atopic-related genes, 
including the itch-inducing chemokine CXCL10 
To ask how neutrophils might promote itch in the MC903 model, we examined the 
transcriptional changes in skin and sensory ganglia isolated from non-itchy neutrophil-
depleted animals and from the TSLPR-/- mice, which scratched robustly. In both the 
neutrophil-depleted and TSLPR-/- skin, several AD-associated cytokines were similarly 
dysregulated, including Il33 (Figure 4A, Figure 4-Figure Supplement 1A). Expression of 
epithelial-derived cytokines and chemokines Tslp, Cxcl1, Cxcl2, Cxcl3, and Cxcl5 were 
unaffected by either loss of TSLPR or neutrophil depletion (Figure 4B), suggesting 
these molecules are produced by skin cells even when the MC903-evoked immune 
response is compromised. Among the hundreds of MC903-dependent genes we 
examined, only a handful of genes were uniquely affected by aGr1 treatment. One such 
gene was Cxcl10, a chemokine known to be released by skin epithelial cells, 
neutrophils, and other myeloid cells (Hashimoto et al., 2018; Ioannidis et al., 2016; 
Kanda et al., 2007; Koga et al., 2008; Michalec et al., 2002; Padovan et al., 2002; 
Tamassia et al., 2007). Cxcl10 expression was increased in TSLPR-/- but not neutrophil-
depleted skin (Figure 4B, Figure 4-Figure Supplement 1A). CXCL10 has been 
previously shown to drive acute itch in a model of allergic contact dermatitis via CXCR3 
signaling in sensory neurons (Qu et al., 2015), and is elevated in skin of AD patients 
(Mansouri and Guttman-Yassky, 2015). Expression of Cxcl9 and Cxcl11, two other 
CXCR3 ligands that are elevated in AD but have an unknown role in itch, was also 
decreased in AD skin of neutrophil-depleted mice (Figure 4B).  
 
CXCR3 signaling is necessary for MC903-evoked chronic itch 
We hypothesized that neutrophil-dependent upregulation of CXCL10 activates sensory 
neurons to drive itch behaviors. Consistent with this model, neutrophil depletion 
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attenuated the expression of activity-induced immediate early genes (Vgf, Junb) in the 
TG, suggestive of neutrophil-dependent sensory neuronal activity in the MC903 model 
(Figure 4C, Figure 4-Figure Supplement 1B). We found that neutrophils also contributed 
to other sensory neuronal phenotypes in the model. For example, we observed that 
expression of Lcn2, a marker of neuropathic itch, and activity-induced genes Fos and 
Junb were not increased in spinal cord isolated from neutrophil-depleted animals after 
MC903 treatment, indicating that neutrophil-dependent scratching behaviors may 
indeed drive changes in the CNS (Figure 4D). We also observed that neutrophil-
depleted animals displayed no skin hyperinnervation at day two (Figure 4E). This result 
was surprising because we did not observe significant neutrophil infiltration at this early 
time point, but these data suggest that low numbers of neutrophils are sufficient to 
mediate these early effects.  
 
To test our model wherein CXCL10 activation of CXCR3 drives neutrophil-dependent 
itch, we first asked whether this CXCR3 ligand is in fact released in MC903-treated skin. 
We performed ELISA on cheek skin homogenate and found that CXCL10 protein was 
increased in MC903-treated skin, but not in skin from neutrophil-depleted mice (Figure 
4F). To test whether CXCR3 signaling directly contributes to MC903-evoked itch, we 
asked whether acute blockade of CXCR3 signaling using the antagonist AMG 487 (Qu 
et al., 2015) affected scratching behaviors in the MC903 model. We found that the 
CXCR3 antagonist strongly attenuated scratching behaviors on days five, eight, and 
twelve (Figure 4G), with the greatest effect at day eight. In contrast, CXCR3 blockade 
did not attenuate scratching behaviors in naive mice injected with the pruritogen 
chloroquine (Figure 4G), demonstrating that CXCR3 signaling contributes to chronic itch 
but is not required for scratching in response to acute pruritogens. Thus, we propose 
that neutrophils promote chronic itch via upregulation of CXCL10 and subsequent 
activation of CXCR3 (Figure 5). 
 
 
DISCUSSION 
 
There is great interest in unraveling the neuroimmune interactions that promote acute 
and chronic itch. Here, we show that neutrophils are essential for the early development 
of MC903-evoked itch. We further show that the acute recruitment of neutrophils to the 
skin is sufficient to drive itch behaviors within minutes of infiltration. While neutrophils 
are known to release a variety of pruritogens, their roles in itch and AD were not studied 
(Hashimoto et al., 2018). Only a few studies have even reported the presence of 
neutrophils in human AD lesions (BS et al., 2012; Koro et al., 1999; Mihm et al., 1976; 
Shalit et al., 1987). Neutrophils have been implicated in psoriatic inflammation and 
inflammatory pain (Carreira et al., 2013; Cunha et al., 2008; Pinho-Ribeiro et al., 2018; 
Sumida et al., 2014), where they are thought to rapidly respond to tissue injury and 
inflammation (Kim and Luster, 2015; Kolaczkowska and Kubes, 2013), but they have 
not been directly linked to itch. A previous study showed that the neutrophil 
chemoattractant Cxcl1 was elevated in a mouse model of dry skin itch (Wilson et al., 
	 25 
2013a). While tissue damage can trigger upregulation of neutrophil chemoattractants 
and neutrophil infiltration, Cxcl1 expression was upregulated both in scratched and 
unscratched itchy skin, suggesting that upregulation of CXCL1, and subsequent 
neutrophil infiltration, is not simply a consequence of tissue damage or the itch-scratch 
cycle.  
 
TSLP signaling triggers development of a Type 2 immune response, which is crucial for 
the progression of atopic disease. For example, Th2 cytokines, most notably IL-4 and 
IL-13, are thought to drive the transition from the acute to chronic phase of human AD, 
and IL4Rα signaling was recently shown to mediate inflammation and itch in the second 
week of the MC903 AD mouse model (Oetjen et al., 2017). Interestingly, the same study 
showed that IL-4 sensitizes the population of itch sensory neurons that responds to 
TSLP. Based upon their observation, and because TSLP is induced early on in the 
MC903 model, we expected TSLP to contribute to early MC903 itch. We were surprised 
to find that TSLPR signaling is dispensable for itch behaviors in the first week of the 
model, and is only required for itch in the second week. In light of our observation that 
neutrophils are required for early MC903 itch, and that TSLPR signaling is necessary for 
increased IL-4 production, we hypothesize that TSLPR signaling plays a key role in 
later, IL-4-dependent itch, whereas early itch is independent of IL-4. Our findings align 
well with a recent study showing that TSLP and IL4 act on overlapping sensory neuron 
populations and that neuronal IL4Rα promotes itch during the second week of the 
MC903 model (Oetjen et al., 2017). 
 
Given the large magnitude of the itch deficit in the neutrophil-depleted mice, we were 
surprised to find fewer expression differences in MC903-dependent, AD-associated 
genes between neutrophil depleted and non-depleted mice than were observed 
between WT and TSLPR-/- mice. One of the few exceptions were the Th1-associated 
genes Cxcl9/10/11 (Brunner et al., 2017; Ewald et al., 2017). We found that induction of 
these genes and CXCL10 protein was completely dependent on neutrophils. While our 
results do not identify the particular cell type(s) responsible for neutrophil-dependent 
CXCL10 production, a number of cell types present in skin have been shown to produce 
CXCL10, including epithelial keratinocytes, myeloid cells, and sensory neurons (Flier et 
al., 2001; Hashimoto et al., 2018; Ioannidis et al., 2016; Kanda et al., 2007; Koga et al., 
2008; Michalec et al., 2002; Padovan et al., 2002; Steain et al., 2011; Tamassia et al., 
2007). We also observed striking differences in neutrophil-dependent gene expression 
in the spinal cord, where expression of activity-induced genes and the chronic itch gene 
Lcn2 were markedly attenuated by loss of neutrophils. Our observations newly implicate 
neutrophils in setting the stage for the acute-to-chronic itch transition by triggering 
molecular changes necessary to develop a chronic, itchy lesion.  
 
Additionally, we demonstrate a novel role of CXCR3 signaling in MC903-induced itch. 
The CXCR3 ligand CXCL10 contributes to mouse models of acute and allergic itch (Liu 
et al., 2016; Qu et al., 2015); however, its role in chronic itch was previously unknown. 
Our results show that CXCL10 upregulation is dependent on neutrophils and that 
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CXCR3 blockade dramatically attenuates itch behaviors. Our findings are in alignment 
with a recent study showing that dupilumab, a new AD drug that blocks IL4Rα, a major 
downstream effector of the TSLP signaling pathway, does not significantly reduce 
CXCL10 levels in human AD lesions (Hamilton et al., 2014). Taken together, this 
suggests that the TSLP-IL-4 and neutrophil-CXCL10 pathways are not highly 
interdependent, and supports our findings that Il4 is robustly upregulated in the absence 
of neutrophils. Additionally, targeting IL4Rα has been successful in treating itch and 
inflammation in some, but not all, AD patients (Simpson et al., 2016). We propose that 
biologics or compounds targeting neutrophils and/or the CXCR3 pathway may be useful 
for AD that is incompletely cleared by dupilumab monotherapy. Drugs targeting 
neutrophils are currently in clinical trials for the treatment of psoriasis, asthma, and 
other inflammatory disorders. For example, MDX-1100, a biologic that targets CXCL10, 
has already shown efficacy for treatment of rheumatoid arthritis in phase II clinical trials 
(Yellin et al., 2012). While rheumatoid arthritis and AD have distinct etiologies (Scott et 
al., 2010), our work indicates that CXCL10 or CXCR3 may be promising targets for 
treating chronic itch. Our findings may be applicable to other itch disorders such as 
psoriasis and ACD where neutrophil chemoattractants and/or CXCL10 are also 
elevated. Overall, our data suggest that neutrophils incite early itch and inflammation in 
the development of AD through several mechanisms, including: 1) directly triggering itch 
upon infiltration into the skin (e.g. by release of known sensitizing/itchy lipids such as 
PGE2 and LTB4, Figure 4) and, 2) indirectly triggering itch by altering expression of 
known pruritogens (e.g. induction of Cxcl10 expression; (Flier et al., 2001; Hashimoto et 
al., 2018; Ioannidis et al., 2016; Kanda et al., 2007; Koga et al., 2008; Michalec et al., 
2002; Padovan et al., 2002; Tamassia et al., 2007). These direct and indirect 
mechanisms for neutrophil-dependent itch may explain why neutrophils have a dramatic 
effect on scratching behaviors on not only day eight but also day five of the model, 
when neutrophils are recruited in large numbers, but CXCR3 ligands are not as robustly 
induced. 
  
More generally, our study provides a framework for understanding how and when 
known human disease genes contribute to the distinct stages of chronic itch 
pathogenesis. Our analysis of MC903-evoked transcriptional changes suggests we may 
be able to extend findings in the model not only to atopic dermatitis, but also to related 
disorders, including specific genetic forms of atopy. For example, we provide evidence 
that the MC903 model may also model the filaggrin loss-of-function mutations, which 
are a key inciting factor in human heritable atopic disease (Palmer et al., 2006; 
Schuttelaar et al., 2009). There are many rich datasets looking at mature patient lesions 
(BS et al., 2012; Ewald et al., 2017; Guttman-Yassky et al., 2009; Jabbari et al., 2012; Li 
et al., 2014; Suárez-Fariñas et al., 2015) and datasets for mature lesions in other 
mouse models of chronic itch (Liu et al., 2016; Oetjen et al., 2017; Swindell et al., 2011; 
2017). Our study adds a temporal frame of reference to these existing datasets to probe 
the function of human disease genes in AD in greater detail. Furthermore, we have 
mapped the time course of gene expression changes in primary sensory ganglia and 
spinal cord during chronic itch development. We show that the MC903 model 
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recapitulates several hallmarks of neuropathic disease on a time course much shorter 
than has been reported for chronic itch, or chronic pain. Nervous system tissues are 
extremely difficult to obtain from human AD patients, and thus little is known regarding 
the neuronal changes in chronic itch disorders in both mouse models and human 
patients.  Our findings can now be compared to existing and future datasets examining 
neuronal changes in chronic pain, diabetic neuropathy, shingles, neuropathic itch, 
psoriasis, and other inflammatory disorders where neuronal changes are poorly 
understood but clearly contribute to disease progression. The early changes we see in 
skin innervation, sensory ganglia, and spinal cord dovetail nicely with recent studies 
examining neuroimmune interactions in other inflammatory conditions (Baral et al., 
2018; Blake et al., 2018; Pinho-Ribeiro et al., 2018), which all implicate early 
involvement of sensory neurons in the pathogenesis of inflammatory diseases. 
 
 
MATERIALS AND METHODS 
 
Mouse studies 
All mice were housed in standard conditions in accordance with standards approved by 
the Animal Care and Use Committee of the University of California Berkeley (12 hr light-
dark cycle, 21 ˚C). Wild-type C57Bl6 mice were obtained from Charles River or Jackson 
Laboratories or raised in-house. TSLPR-/- mice were kindly provided by Dr. Steven 
Ziegler (Crlf2tm1Jni; (Carpino et al., 2004) and were backcrossed onto C57Bl6. All 
experiments were performed under the policies and recommendations of the 
International Association for the Study of Pain and approved by the University of 
California Berkeley Animal Care and Use Committee. Genotypes were assessed using 
standard PCR. 
  
MC903 model of atopic dermatitis 
MC903 (R&D Systems) was applied to the mouse cheek (20 μl of 0.2 mM in ethanol) 
once per day for 1-12 days. 100% ethanol was used as a vehicle control. 3-7 days prior 
to the beginning of treatment, mice were singly housed and their cheeks were shaved. 
All MC903 studies were performed on 8-12 week old age-matched mice. Behavior, 
RNA-seq, flow cytometry, and immunohistochemistry were performed on days 1, 2, 3, 5, 
8 and/or 12. Behavioral scoring was performed while blind to experimental condition 
and mouse genotype. Itch behavior was scored for the first 30 min. For AMG 487 
experiments in the MC903 model, 50 µL 3.31 mM AMG 487 (Tocris) or 20% HPCD-PBS 
vehicle was injected subcutaneously one hour prior to recording behavior (Qu et al., 
2015). Both bout number and length were recorded. 
  
MC903 RNA isolation and sequencing 
At Days 1 (six hours post-treatment), 2, 5, and 8 post-treatment, mice treated with 
MC903 or vehicle were euthanized via isoflurane and cervical dislocation. Cheek skin 
was removed, flash-frozen in liquid nitrogen, and cryo-homogenized with a mortar and 
pestle. Ipsilateral trigeminal ganglia were dissected and both skin and trigeminal ganglia 
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were homogenized for three minutes (skin) or one minute (TG and spinal cord) in 1 mL 
RNAzol RT (Sigma-Aldrich). Thoracic spinal cord was dissected from mice treated with 
40 µL MC903 or ethanol on the shaved rostral back and homogenized in 1 mL RNAzol. 
Large RNA was extracted using RNAzol RT per manufacturer’s instructions. RNA 
pellets were DNase treated (Ambion), resuspended in 50 µL DEPC-treated water, and 
subjected to poly(A) selection and RNA-seq library preparation (Apollo 324). Single-end 
read sequencing (length = 50 bp) was performed by the QB3 Vincent G. Coates 
Genomic Sequencing Laboratory (UC Berkeley) on an Illumina HiSeq4000. See 
Supplementary Table 1 for number of mice per experimental condition and number of 
mapped reads per sample. 
  
MC903 RNA sequencing analysis 
Reads were mapped to the mm10 mouse genome using Bowtie2 and Tophat 
(Langmead and Salzberg, 2012; Langmead et al., 2009). For a given time point, 
replicate measurements for each gene from treated and control mice were used as 
input for DESeq (R) and genes with padjusted < 0.05 (for skin and spinal cord) or padjusted < 
0.1 (for trigeminal ganglia) for at least one time point were retained for analysis (Anders 
and Huber, 2010).  For the skin dataset, we collated a set of AD-related immune cell 
markers, cytokines, atopic dermatitis disease genes, neurite outgrown/axonal guidance 
genes, and locally expressed neuronal transcripts, and from this list visualized genes 
that were significantly differentially expressed for at least one time point. For the 
trigeminal ganglia dataset, we plotted all genes that were significantly differentially 
expressed for at least one time point. Genes from these lists were plotted with clustering 
using heatmap2 (R). 
  
Custom gene groups 
Genes were clustered into functional groups and significance was evaluated using a 
permutation test. Briefly, we first tabulated the absolute value of the log2 fold change of 
gene expression (between MC903 and EtOH) of each gene in a given group of n genes 
in turn, and then we calculated the median of these fold change values, ztrue. We then 
drew n random genes from the set of all genes detected in the samples and computed 
the median log2 fold change as above using this null set, znull. Repeating the latter 
10,000 times established a null distribution of median log2 fold change values; we took 
the proportion of resampled gene groups that exhibited (ztrue ≥ znull) as an empirical p-
value reporting the significance of changes in gene expression for a given group of n 
genes. 
  
Flow Cytometry 
Skin samples were collected from the cheek of mice at the indicated time points with a 
4- or 6-mm biopsy punch and minced into smaller pieces with scissors. Myeloid cells 
were digested for 1h at 37 ˚C using Liberase (Roche). At the end of the digestion, cells 
were washed in FACS buffer (PBS with 0.5% FCS and 2 mM EDTA) and filtered 
through a 70 or 100 µm cell strainer (Falcon, #352350). Cells were stained with 
LIVE/DEAD fixable stain Aqua (Invitrogen), then blocked with anti-CD16/32 (UCSF 
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Core) and stained with fluorophore-conjugated cKit-Biotin (ACK2) (secondary stain with 
SA-FITC), anti-CD11b-PB (M1/70, eBiosciences), Ly6C-PerCP (HK1.4), CD49b-PECy7 
(DX5), CD45.2-APCCy7 (104), FceRI-PE (MAR-1), Ly6G-AF700 (1A8, all from 
eBiosciences). 10ml of counting beads (Invitrogen) were added after the last wash to 
measure absolute cell counts. CD4+ T cells were digested for 30 minutes at 37˚C using 
Collagenase VIII (Sigma). At the end of the digestion, cells were washed in RPMI buffer 
(RPMI, 5% FCS, 1% penicillin-streptomycin, 2 mM L-glutamine, 10 mM HEPES buffer, 
1 mM sodium pyruvate). Cells were blocked with antiCD16/32 (UCSF Core) and stained 
with anti-CD45-APC780 (30-F11; eBiosciences), Cd11b-PECy7 (M1/70; BD 
Biosciences), B220-PECy7 (RA3-6B2; Tonbo Biosciences), Cd11c-PECy7 (N418; 
eBiosciences), CD3-FITC (145-2C11; eBiosciences), CD8-BV785 (53-6.7; Biolegend), 
CD4-PE (GK1.5; BD Biosciences), 647-gdTCR (GL3; Biolegend). 10µl of counting 
beads (Invitrogen) were added after the last wash to measure absolute cell counts, and 
samples were resuspended in DAPI LIVE/DEAD (Invitrogen). Single cell suspensions 
were analyzed on an LSR II or LSR Fortessa (BD Biosciences), and data were analyzed 
using FlowJo (TreeStar, v.9.9.3) software. One skin sample was excluded from analysis 
due to clear blood contamination. Blood samples were collected from saphenous vein or 
from terminal bleed following decapitation. Red blood cells were lysed using ACK lysis 
buffer (Gibco, #A10492-01), washed with FACS buffer (PBS with 5% FBS and 2 mM 
EDTA), and blocked with antiCD16/32 (UCSF Core). Cells were stained with Ly6G-PE 
(1A8; BD Biosciences), Cd11b-PB (M1/70, eBiosciences), Ly6C-PerCP (HK1.4, 
Biolegend), and aGr1-APCCy7 (RB6-8C5, eBiosciences).   
 
Human keratinocyte RNA sequencing 
Normal human epidermal keratinocytes from juvenile skin (PromoCell #C-12001) were 
cultured in PromoCell Keratinocyte Growth Medium 2 and passaged fewer than 5 times. 
Cells were treated for three hours at room temperature with 100 μM SLIGRL or vehicle 
(Ringer’s + 0.1% DMSO). Total RNA was extracted by column purification (Qiagen 
RNeasy Mini Kit). RNA was sent to the Vincent J. Coates Sequencing Laboratory at UC 
Berkeley for standard library preparation and sequenced on an Illumina HiSeq2500 or 
4000. Sequences were trimmed (Trimmomatic), mapped (hg19, TopHat) and assigned 
to transcripts using htseq-count. Differential gene expression was assessed using R 
(edgeR). 
 
IHC of whole-mount skin 
Staining was performed according to Hill et al. (Hill et al., 2018). Briefly, 8-week-old 
mice were euthanized and the cheek skin was shaved and tape-stripped. The removed 
skin was fixed overnight in 4% PFA, then washed in PBS (3X for 10 min each). Dermal 
fat was scraped away with a scalpel and skin was washed in PBST (0.3% Triton X-100; 
3X for two hours each) then incubated in 1:500 primary antibody (Rabbit anti beta-
Tubulin III: Abcam #ab18207) in blocking buffer (PBST with 5% goat serum and 20% 
DMSO) for 6 days at 4°C. Skin was washed as before and incubated in 1:500 
secondary antibody (Goat anti-Rabbit Alexa 594; Invitrogen #R37117) in blocking buffer 
for 3 days at 4°C. Skin was washed in PBST, serially dried in methanol: PBS solutions, 
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incubated overnight in 100% methanol, and finally cleared with a 1:2 solution of benzyl 
alcohol: benzyl benzoate (BABB; Sigma) before mounting between No. 1.5 coverglass. 
Sectioned and whole mount skin samples were imaged on a Zeiss LSM 880 confocal 
microscope with OPO using a 20x water objective. Image analysis was performed using 
a custom macro in FIJI. Briefly, maximum intensity z-projections of the beta-tubulin III 
channel were converted to binary files that underwent edge-detection analysis. Regions 
were defined by circling all stained regions. Region sizes and locations were saved. 
  
IHC of sectioned trigeminal ganglia 
TG were dissected from 8 to 12 week old adult mice and post-fixed in 4% PFA for one 
hour. TG were cryo-protected overnight at 4°C in 30% sucrose-PBS, embedded in OCT, 
and then cryosectioned at 14 μm onto slides for staining. Slides were washed 3x in 
PBST (0.3% Triton X-100), blocked in 2.5% horse serum + 2.5% BSA PBST, washed 
3X in PBST, blocked in endogenous IgG block (1:10 F(ab) anti-mouse IgG (Abcam 
ab6668) + 1:1000 Rat anti-mouse CD16/CD32 (UCSF MAB Core) in 0.3% PBST), 
washed 3X in PBST and incubated overnight at 4°C in 1:1000 primary antibody in PBST 
+ 0.5% horse serum + 0.5% BSA. Slides were washed 3x in PBS, incubated 2 hr at RT 
in 1:1000 secondary antibody, washed 3X in PBS, and then incubated 30 min in 1:2000 
DAPI-PBS. Slides were washed 3x in PBS and mounted in Fluoromount-G with No. 1.5 
coverglass. Primary antibodies used: Mouse anti-CD45 (eBioscience #14-054-82) and 
Chicken anti-Peripherin (Abcam #39374). Secondary antibodies used: Goat anti-
Chicken Alexa 594 (ThermoFisher #A11042) and Goat anti-Mouse Alexa 488 (Abcam 
#150117). DAPI (ThermoFisher #D1306) was also used. Imaging of TG IHC 
experiments was performed on an Olympus IX71 microscope with a Lambda LS-xl light 
source (Sutter Instruments). For TG IHC analysis, images were analyzed using 
automated scripts in FIJI (ImageJ) software. Briefly, images were separated into the 
DAPI, CD45, and Peripherin channels. The minimum/maximum intensity thresholds 
were batch-adjusted to pre-determined levels, and adjusted images were converted to 
binary files. Regions were defined by circling all stained regions with pre-determined 
size-criteria. Region sizes and locations were saved. All ImageJ macros are available 
upon request. All scripts are available upon request. 
 
Neutrophil depletion 
Neutrophils were acutely depleted using intraperitoneal injection with 250 µg aGR1 in 
PBS (clone RB6-8C5, a gift from D. Portnoy, UC Berkeley, or Biolegend), 16-24 hours 
before behavioral and flow cytometry experiments. Depletion was verified using flow 
cytometry on blood collected post-mortem. For longer depletion experiments using the 
MC903 model, mice were injected (with 250 µg aGR1 in PBS or PBS vehicle, i.p.) 
beginning one day prior to MC903 administration and each afternoon thereafter through 
day 7 of the model, and blood was collected via saphenous venipuncture at days 3, 5, 
or by decapitation at day 8 to verify depletion. 
  
CXCL10 ELISA measurements in skin 
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Neutrophil-depleted or uninjected mice were treated with MC903 or ethanol for 7 days. 
On day 8, 6mm biopsy punches of cheek skin were harvested, flash-frozen in liquid 
nitrogen, cryo-homogenized by mortar and pestle, and homogenized on ice for three 
minutes at maximum speed in 0.5 mL of the following tissue homogenization buffer (all 
reagents from Sigma unless stated otherwise): 100 mM Tris, pH 7.4; 150 mM NaCl, 1 
mM EGTA, 1 mM EDTA, 1% Triton X-100, and 0.5% Sodium deoxycholate in ddH2O; 
on the day of the experiment, 200 mM fresh PMSF in 100% ethanol was added to 1mM, 
with 1 tablet cOmplete protease inhibitor (Roche) per 50 mL, and 5 tablets PhosSTOP 
inhibitor (Roche) per 50 mL buffer. Tissues were agitated in buffer for two hours at 4°C, 
and centrifuged at 13,000 rpm for 20 minutes at 4°C. Supernatants were aliquoted and 
stored at -80C for less than one week after isolation. After thawing, samples were 
centrifuged at 10,000 rpm for five minutes at 4°C. Protein content of skin homogenates 
was quantified by BCA (Thermo Scientific) and homogenates were diluted to 2 mg/mL 
protein in PBS and were subsequently diluted 1:2 in Reagent Diluent (R&D Systems). 
CXCL10 protein was quantified using the Mouse CXCL10 Duoset ELISA kit (R&D 
Systems; #DY466-05) according to manufacturer’s instructions. Plate was read at 450 
nm and CXCL10 was quantified using a seven-point standard curve (plus blank and 
buffer controls) and fitted with a 4-parameter logistic curve. 
  
Acute itch behavior 
Itch and acute pain behavioral measurements were performed as previously described 
(Morita et al., 2015; Tsunozaki et al., 2013; Wilson et al., 2013b). Mice were shaved one 
week prior to itch behavior. Compounds injected: 1 µg carrier-free CXCL1 (R&D 
systems) in PBS, 3.31 mM AMG 487 (Tocris, prepared from 100 mM DMSO stock) in 
20% HPCD-PBS, 50 mM Chloroquine diphosphate (Sigma) in PBS (Chloroquine, 
CXCL1), along with corresponding vehicle controls. Acute pruritogens were injected 
using the cheek model (20 µL, i.d.) of itch, as previously described (Shimada and 
LaMotte, 2008). AMG 487 (50 µL) or vehicle was injected s.c. into the rostral back skin 
one hour prior to recording of behavior (Qu et al 2015). Behavioral scoring was 
performed as described above. 
  
Lipidomics 
Skin was collected from the cheek of mice post-mortem with a 6-mm biopsy punch and 
immediately flash-frozen in liquid nitrogen. Lipid mediators and metabolites were 
quantified via liquid chromatography-tandem mass spectrometry (LC-MS/MS) as 
described before (Moltke et al., 2012; Sapieha et al., 2011). In brief, skin was 
homogenized in cold methanol to stabilize lipid mediators. Deuterated internal 
standards (PGE2-d4, LTB4-d4, 15-HETE-d8, LXA4-d5, DHA-d5, AA-d8) were added to 
samples to calculate extraction recovery. LC-MS/MS system consisted of an Agilent 
1200 Series HPLC, Luna C18 column (Phenomenex, Torrance, CA, USA), and AB 
Sciex QTRAP 4500 mass spectrometer. Analysis was carried out in negative ion mode, 
and lipid 30 mediators quantified using scheduled multiple reaction monitoring (MRM) 
mode using four to six specific transition ions per analyte. 
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Statistical analyses 
Different control experimental conditions (e.g. uninjected versus PBS-injected animals) 
were pooled when the appropriate statistical test showed they were not significantly 
different (Supplementary Table 2). For all experiments except RNA-seq (see above), 
the following statistical tests were used, where appropriate: Student’s t-test, one-way 
ANOVA with Tukey-Kramer post hoc comparison, and two-way ANOVA with Tukey 
Kramer or Sidak’s post-hoc comparison. Bar graphs show mean ± SEM. Statistical 
analyses were performed using PRISM 7 software (GraphPad). For all p values, 
*=0.01<p<0.05, **=0.001<p<0.01, ***=0.0001<p<0.001, and ****=p<0.0001. 
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FIGURES  
 
 
Figure 1. The MC903 model parallels the progression of human atopic disease 
and suggests a temporal sequence of AD pathogenesis. A. Exact permutation test 
(10,000 iterations, see Methods) for significance of mean absolute log2 fold change in 
gene expression at Day 8 (MC903 vs. ethanol) of custom-defined groups of genes for 
indicated categories). B. Log2 fold change in gene expression (MC903 vs. ethanol) in 
mouse skin at indicated time points for key immune and mouse/human atopic dermatitis 
genes that were significantly differentially expressed for at least one time point in the 
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MC903 model. Only genes from our initial list (see Methods) differentially expressed at 
corrected p < 0.05 and changing > 2-fold between treatments for at least one condition 
are shown. Green bars = increased expression in MC903 relative to ethanol; magenta = 
decreased expression. D1 = 6 hours post-treatment; D2 = Day 2; D5 = Day 5; D8 = Day 
8. C. Scratching behavior of mice treated with MC903 or ethanol for indicated length of 
time (two-way ANOVA: ****pinteraction< 0.0001, F(2,409) = 13.25; Sidak’s multiple 
comparisons: pday 3 = 0.1309, n=62,51 mice; *pday 5 = 0.0171, n=69,56 mice; ****pday 8 < 
0.0001, n=92,85 mice). D. Log2 fold change in gene expression of neutrophil 
chemoattractants (upper), Th2 cytokines (middle) and T cell chemoattractants (lower, 
from RNA-seq data). E. Neutrophil counts in MC903- and ethanol-treated skin at 
indicated time points (two-way ANOVA: **ptreatment= 0.0023, F(1,102) = 9.82; Sidak’s 
multiple comparisons: pday 2 > 0.999, n=4,4 mice; pday 3 = 0.9801, n=5,5 mice; ***pday 5 = 
0.0003, n=6,8 mice; ***pday 8 = 0.0001, n=40,38 mice).  F. Basophil counts in MC903- 
and ethanol-treated skin at indicated time points (two-way ANOVA: *ptreatment= 0.0215, 
F(1,102) = 5.45; Sidak’s multiple comparisons: pday 2 > 0.999, n=4,4 mice; pday 3 = 
0.8566, n=5,5 mice; pday 5 = 0.1280, n=6,8 mice; **pday 8 = 0.0010, n=40,38 mice). G. 
CD4+ T cell counts in MC903- and ethanol-treated skin at indicated time points (two-way 
ANOVA: **ptime= 0.0042, F(1,44) = 9.10; pday 3 = 0.9998, n=8,6 mice; pday 5 = 0.2223, 
n=9,8 mice; **pday 8 = 0.0021, n=11,8 mice). H. Representative maximum intensity Z-
projections from immunohistochemistry (IHC) of whole-mount mouse skin on Day 2 of 
the MC903 model. Skin was stained with neuronal marker beta-tubulin III (BTIII; green). 
Hair follicle autofluorescence is visible in the magenta channel. Images were acquired 
on a confocal using a 20x water objective. I. Quantification of innervation (see Methods) 
of mouse skin as determined from BTIII staining (*p = 0.012; two-tailed t-test (t =3.114; 
df =9); n = 7,4 images each from 2 mice per treatment). Day 1 IHC results as follows: 
31.78 ± 18.39 % (MC903) and 31.51 ± 16.43 % (EtOH); p = 0.988; two-tailed unpaired t-
test; n = 6 images each from 2 mice per treatment.   
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Figure 2. Neutrophils are necessary and sufficient for itch behaviors. A. Scratching 
behavior of uninjected and PBS-injected mice (combined) and aGr1-injected mice 
treated with MC903 or ethanol for indicated length of time (two-way ANOVA: 
****pinteraction < 0.0001, F(4,447) = 7.16; Tukey’s multiple comparisons: pday 3 > 0.05, 
n=62,51,17 mice; *pday 5 = 0.0154, pday 5 =0.9854, pday 5 =0.2267, n=69,56,17 mice; 
****pday 8 < 0.0001, ***pday 8 = 0.0007, pday 8 = 0.1543, n=92,85,17 mice). B. Neutrophil 
count from cheek skin of uninjected/PBS-injected MC903- and ethanol-treated, and 
aGr1-injected MC903-treated mice on day 8 (one-way ANOVA: ****p < 0.0001, F(2,92) 
= 10.59; Tukey’s multiple comparisons: ****pMC903 vs. EtOH < 0.00001, n=40,38 mice; 
pMC903 vs. aGr1 MC903 = 0.0109, n=40,17 mice). C. Basophil count from cheek skin of 
uninjected/PBS-injected MC903- and ethanol-treated, and aGr1-injected MC903-treated 
mice on day 8 (one-way ANOVA: **p = 0.0025, F(2,92) = 6.397; Tukey’s multiple 
comparisons: pMC903 vs. aGr1 MC903 = 0.4848, n=40,17 mice). D. CD4+ T cell count from 
cheek skin of uninjected/PBS-injected MC903- and ethanol-treated, and aGr1-injected 
MC903-treated mice on day 8 (two-way ANOVA: *ptreatment = 0.0286, F(1,26) = 5.373; 
Holm-Sidak multiple comparisons for PBS versus aGr1: pMC903 = 0.8127, n=8,10 mice; 
pEtOH = 0.7131, n=6,6 mice). Control MC903 and EtOH data from Figure 2B-C are also 
displayed in Figure 1. E. Scratching behavior of mice immediately after injection of 1 µg 
CXCL1 or PBS (i.d. cheek). For neutrophil-depletion experiments, mice received 250 µg 
anti-Gr1 (aGr1) 20 hours prior to cheek injection of CXCL1 or PBS (one-way ANOVA: 
****p <  0.0001, F(4,88) = 75.53; Tukey’s multiple comparisons: *pCXCL1 vs. PBS = 0.0126, 
n=36,31 mice; paGr1-CXCL1 vs. aGr1-PBS > 0.9999, n=10,10 mice; paGr1-CXCL1 vs. PBS = 0.9986, 
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n=10,31 mice). F. Scratching behavior of WT and TSLPR-/- (TSLPR KO) mice treated 
with MC903 or ethanol for indicated length of time (two-way ANOVA: ****pinteraction < 
0.0001, F(9,657) = 4.93; Tukey’s multiple comparisons: ****pday 8 < 0.0001, *pday 8 = 
0.0194, **pday 8 = 0.0039, n=92,85,36,26 mice; ****pday 12 < 0.0001, **pday 12 = 0.0028, 
pday 12  = 0.7061, n=26,26,27,23 mice). G. Neutrophil count from cheek skin of wild-type 
MC903- and ethanol-treated, and TSLPR-/- MC903-treated mice on day 5 (two-way 
ANOVA: **pgenotype = 0.0025, F(2,125) = 6.28; Tukey’s multiple comparisons: ****pday 5 WT 
MC903 vs. WT EtOH < 0.0001, n=6,8 mice; pday 5 WT MC903 vs. KO MC903 = 0.2198, n=6,6 mice; *pday 
5 WT EtOH vs. KO MC903 = 0.0212, n=8,6 mice). H. Basophil count from cheek skin of wild-type 
MC903- and ethanol-treated, and TSLPR-/- MC903-treated mice on day 8 (two-way 
ANOVA: **pgenotype = 0.0023, F(2,117) = 6.38; Tukey’s multiple comparisons: ***pday 8 WT 
MC903 vs. WT EtOH = 0.0003, n=40,38 mice; ***pday 8 WT MC903 vs. KO MC903 = 0.0003, n=40,15 
mice; pday 8 WT EtOH vs. KO MC903 = 0.5768, n=38,15 mice). I. CD4+ T cell count from cheek 
skin of wild-type MC903- and ethanol-treated, and TSLPR-/- MC903-treated mice on day 
8 (one-way ANOVA: **p = 0.0053, F(2,24) = 6.564; Tukey’s multiple comparisons: *pWT 
MC903 vs. WT EtOH = 0.0163, n=11,8 mice; *p MC903 vs. KO MC903 = 0.0130, n=11,8 mice; pWT EtOH 
vs. KO MC903 = 0.9953, n=8,8 mice). Wild-type MC903 and EtOH data from 2F-H are also 
displayed in Figure 1.   
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Figure 3. The MC903 model induces rapid and robust changes in neurons. A. 
Exact permutation test (10,000 iterations, see Methods) for significance of mean 
absolute log2 fold change in gene expression at Day 8 (MC903 vs. ethanol) of custom-
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defined groups of genes for indicated categories. B. Log2 fold change in gene 
expression (MC903 vs. ethanol) in mouse trigeminal ganglia (TG) at indicated time 
points for all genes which were significantly differentially expressed for at least one time 
point in the MC903 model. Green bars = increased expression in MC903 relative to 
ethanol; magenta = decreased expression. C. Representative composite images 
showing immune cells (CD45, green), and sensory neurons (Prph, magenta) with DAPI 
(blue) in sectioned trigeminal ganglia from mice treated with Vehicle or MC903 for five 
days on the cheek. D. Quantification of images examining average number of CD45+ 
cells per section and average ratio of CD45:Peripherin cells per section after five days 
of treatment (p = 0.562 (t=0.6318, df=4), 0.542 (t=0.6660, df=4); two-tailed unpaired t-
tests, n=33-159 fields of view (images) each of both trigeminal ganglia from 3 mice per 
condition treated bilaterally). E. Representative composite images showing immune 
cells (CD45, green), and sensory neurons (Peripherin (Prph), magenta) with DAPI 
(blue) in sectioned trigeminal ganglia from mice treated with Vehicle or MC903 for eight 
days on the cheek. F. Quantification of images examining average number of CD45+ 
cells per section and average ratio of CD45:Peripherin cells per section after eight days 
of treatment (**p = 0.0019 (t=5.977,df=5), **p = 0.0093 (t=4.107,df=4); two-tailed 
unpaired t-tests; n=42-172 fields of view (images) each of both trigeminal ganglia from 3 
EtOH or 4 MC903 animals treated bilaterally). Scale bar = 100 µm. Images were 
acquired on a fluorescence microscope using a 10x air objective. G. Log2 fold change in 
gene expression (MC903 vs. ethanol) in mouse spinal cord on day 8 showing selected 
differentially expressed genes (padjusted < 0.05). 
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Figure 4. Neutrophils are required for induction of the itch-inducing chemokine 
CXCL10. A. Log2 fold change (Day 8 MC903 vs. EtOH) of Th2 genes in skin from 
uninjected wild-type, aGR1-treated, and TSLPR-/- animals. B. Log2 fold change (Day 8 
MC903 vs. EtOH) of chemokine genes in skin from uninjected wild-type, aGr1-treated, 
and TSLPR-/- animals. C. Log2 fold change (Day 8 MC903 vs. EtOH) of activity-induced 
genes in trigeminal ganglia from uninjected wild-type, aGr1-treated, and TSLPR-/- 
animals. D. Log2 fold change (Day 8 MC903 vs. EtOH) of Lcn2  and activity-induced 
genes in spinal cord from uninjected and aGr1-treated wild-type mice on day 8. E. 
Quantification of innervation (see Methods) of MC903 and EtOH-treated mouse skin as 
determined from BTIII staining (p = 0.8985; two-tailed t-test (t =0.1294; df =18); n = 9,11 
images each from 2 mice per treatment. F. CXCL10 levels in skin homogenate as 
measured by ELISA on day 8 of the MC903 model for uninjected animals (left; *p = 
0.029 (t=2.715, df=7); two-tailed t-test; n = 4,5 animals) and animals which received 
aGr1 for 8 days (right; p = 0.43 (t=0.815, df=11); two-tailed t-test; n = 6,6 animals). 
Homogenates were isolated on separate days and so uninjected samples were not 
compared to aGr1-treated samples. G. (Left) Time spent scratching over a thirty minute 
interval on days 5, 8, and 12 of the MC903 model, one hour after mice were injected 
with either 3.31 mM of the CXCR3 antagonist AMG 487 or vehicle (10% HPCD; 50 µL 
s.c. in rostral back); (two-way ANOVA: ****ptreatment < 0.0001, F(1,67) = 50.64; Tukey’s 
multiple comparisons: *pday 5 = 0.0216, n=8,10 mice; ***pday 8 = 0.0007, n=18,21 mice; 
****pday 12 < 0.0001, n=8,8 mice). (Right) Time spent scratching over a thirty minute 
interval one hour after mice were injected with either 3.31 mM of the CXCR3 antagonist 
AMG 487 or vehicle (10% HPCD; 50 µL s.c. in rostral back), and immediately after mice 
were injected with 50 mM chloroquine (20 µL i.d., cheek). p = 0.92 (t=0.0964, df=8); 
two-tailed t-test; n = 5,5 mice.  
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Figure 5. Model of early AD pathogenesis. A. AD induction first results in increased 
protease expression and barrier dysfunction, which drives production of the cytokines 
TSLP and CXCL1 via PAR2 activation in keratinocytes. CXCL1 can recruit neutrophils 
via its receptor CXCR2. Neutrophils may evoke itch by multiple pathways, including 
degranulation and release of proteases and histamine, production of sensitizing lipids 
such as PGE2 and LTB4, and induction of CXCL10 expression, which can activate 
sensory neurons via CXCR3. TSLP activates a number of immune cells to elicit IL-4 
production, including basophils, which results in increased IL-4, recruitment of CD4+ T 
cells, and sensitization of neurons to promote itch later in the model (Oetjen et al. 2017). 
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Figure 1-Figure Supplement 1. Expression of mouse and human itch genes. A. 
Log2 fold change in gene expression (MC903 vs. ethanol) in mouse skin at indicated 
time points for genes implicated in mouse or human acute or chronic itch that were 
significantly differentially expressed for at least one time point in the MC903 model. 
Green bars = increased expression in MC903 relative to ethanol; magenta = decreased 
expression.  
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Figure 1-Figure Supplement 2. Immune cell counts in MC903-treated skin. A. 
Inflammatory monocyte counts in MC903- and ethanol-treated skin at indicated time 
points (two-way ANOVA: *ptreatment= 0.0129, F(1,96) = 6.42; Sidak’s multiple 
comparisons: pday 3 = 0.6933, n=5,5 mice; pday 5 = 0.6536, n=6,8 mice; ****pday 8 < 
0.0001, n=40,38 mice). B. Mast cell counts in MC903- and ethanol-treated skin at 
indicated time points (two-way ANOVA: *ptreatment= 0.0117, F(1,96) = 6.60; Sidak’s 
multiple comparisons: pday 3 = 0.6562, n=5,5 mice; pday 5 = 0.2829, n=6,8 mice; *pday 8 = 
0.0115, n=40,38 mice). Data from mice receiving i.p. injection of PBS (see Figure 4) in 
addition to MC903 or EtOH are also included. C. Eosinophil counts in MC903- and 
ethanol-treated skin at indicated time points (two-way ANOVA: ptreatment= 0.0964, F(1,96) 
= 2.81, n=4,5,5,8,38,38 mice).  
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Figure 1-Figure Supplement 3. Protease receptor activation triggers rapid 
upregulation of neutrophil chemokine genes in human keratinocytes. A. Heat map 
showing log2 fold change in gene expression in cultured human keratinocytes 3 hours 
after SLIGRL treatment (100 µM; bottom; see Figure 1-source data table 7) compared 
to vehicle controls, as measured by RNA-seq. Genes are sorted by descending 
corrected p-value; only significantly differentially expressed (p < 0.05) are displayed.  
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Figure 1-Figure Supplement 4. Expression of neuronal genes and axon guidance 
molecules in skin. A. Log2 fold change in gene expression (MC903 vs. EtOH) in 
mouse skin at indicated time points for markers of locally translated sensory neuronal 
transcripts or genes implicated in neurite remodeling and/or axon guidance that were 
significantly differentially expressed for at least one time point in the MC903 model. 
Green bars = increased expression in MC903 relative to ethanol; magenta = decreased 
expression.  
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Figure 1-Figure Supplement 5. Method of image quantification for whole mount 
skin. A. Representative maximum intensity z-projection of beta tubulin III staining in 
cheek skin. B. Binary image after edge-detection. C. % Area innervated was calculated 
from the percentage of the image area which was occupied by the regions of interest 
(ROIs) outlined in red. 
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Figure 1-Figure Supplement 6. Inflammatory lipids in MC903-treated skin. A. 
Quantification of indicated lipids from 6 mm biopsy punches of cheek skin of MC903- 
and EtOH-treated mice (at day 8) by LC-MS/MS (**p = 0.006 (t=4.148,df=6), *p = 0.024 
(t=3.003,df=6), ***p = 0.0007 (t=6.392,df=6), *p = 0.022 (t=3.058,df=6); two-tailed 
unpaired t-tests; n = 4 mice per group). 
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Figure 2-Figure Supplement 1. aGr1 treatment preferentially depletes neutrophils. 
A. Representative flow cytometry plots of cells collected from blood of mice injected with 
PBS or aGr1 (250 μg, i.p.) once-daily for five days concurrent with daily MC903 topical 
treatment. Shown are CD45.2+CD11b+ cells, plotted by Ly6G and Ly6C signal, with 
neutrophil (Neuts.) and inflammatory monocyte (IMs) populations indicated. Neutrophils 
were defined as Cd11b+Ly6G+Ly6Cmid/high and IMs were defined as Cd11b+Ly6G-
Ly6Chigh (see Methods). B. Representative flow cytometry plot as in A, depicting 
neutrophil and IM populations from blood collected on day 8. C. (Left) Neutrophil counts 
in blood shown as % of Cd11b+ cells from aGr1/MC903 (black triangles) and 
PBS/MC903 (gray circles)-treated animals on days 3, 5, and 8 of the model (two-way 
repeated measures ANOVA: ****ptreatment < 0.0001, F(1,31) = 299.5; Sidak’s multiple 
comparisons: ****pday 3 < 0.0001; ****pday 5 < 0.0001; ****pday 8 < 0.0001, n= 16,17 mice). 
(Right) Inflammatory monocyte counts in blood shown as % of Cd11b+ cells from 
aGr1/MC903 and PBS/MC903-treated animals on days 3, 5, and 8 of the model (two-
	 48 
way repeated measures ANOVA: *ptreatment = 0.0468, F(1,31) = 4.287; Sidak’s multiple 
comparisons: **pday 3 = 0.0015; pday 5 = 0.1918; pday 8 = 0.2013, n= 16,17 mice).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 49 
Figure 2-Figure Supplement 2. CXCL1 rapidly and selectively recruits neutrophils 
to skin. A. Representative flow cytometry plots of cells from cheek skin of mice injected 
with PBS or CXCL1 (1 μg, i.d.). Shown are CD45.2+CD11b+ cells, plotted by Ly6G and 
Ly6C signal, with neutrophil and inflammatory monocyte (IM) populations indicated. B. 
Neutrophil count from cheek skin of mice 5, 15, and 30 minutes after injection of CXCL1 
or PBS (two-way ANOVA: *pinteraction= 0.0239, F(2,21) = 4.48; Sidak’s multiple 
comparisons: p5 min > 0.9999, n=4,5 mice; *pday 15 min = 0.0141, n=4,4 mice; **pday 30 min = 
0.0031, n=3,7 mice).  
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Figure 2-Figure Supplement 3. Neutrophil depletion does not affect chloroquine-
evoked itch. A. Scratching behavior of mice immediately after injection of chloroquine 
(CQ) or PBS (i.d. cheek). For neutrophil-depletion experiments, mice received 250 µg 
anti-Gr1 (aGr1) 20 hours prior to cheek injection of CQ or PBS (two-tailed t-test: ****p <  
0.0001 (t=10.58, df=14); n=6,10 mice).  
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Figure 3-Figure Supplement 1. Method of image quantification for sectioned 
trigeminal ganglia. A. Representative composite image showing CD45 (green), 
Peripherin (magenta), and DAPI (blue). B. Single-channel CD45 image with automated 
min/max intensity thresholding. C. Resultant binary image generated from B. D. Cells 
were counted as the number of regions of interest (ROIs) outlined in blue. 
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Figure 4-Figure Supplement 1. MC903-dependent gene expression changes in 
aGr1-treated and TSLPR-/- animals. A. Heat map showing log2 fold change in gene 
expression (Day 8 MC903 vs. EtOH) for itch-associated genes in wild-type, aGr1-
treated, and TSLPR-/- skin. Green bars = increased expression in MC903 relative to 
ethanol; magenta = decreased expression. B. Heat map showing log2 fold change in 
gene expression (Day 8 MC903 vs. EtOH) for wild-type, aGr1-treated, and TSLPR-/- 
mouse trigeminal ganglia (TG) at indicated time points for all genes which were 
significantly differentially expressed for at least one time point in the MC903 model (See 
Figure 2D). Green bars = increased expression in MC903 relative to ethanol; magenta 
= decreased expression.  
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Chapter 3: Future Perspectives. 
 
Although I was fortunate enough to work on multiple projects throughout my time 
as a PhD student at Berkeley, the central focus of my thesis was atopic dermatitis 
pathogenesis. This research continued to evolve and change throughout the time that I 
was involved in the project, and in fact our data led us in many directions that we did not 
initially expect. In addition, this work was highly collaborative, and multiple authors 
contributed unique ideas, expertise, and experience, each of which added a new 
dimension to the paper. For these reasons, it is easy to imagine many further lines of 
investigation that could be followed in the future.  
 One potential avenue for future research is the role of leukotriene B4 (LTB4) in 
chronic itch, and particularly in the MC903 model of atopic dermatitis. LTB4 is a 
proinflammatory lipid known to play a role in neutrophil swarming (Lämmermann et al., 
2013). Increased levels of LTB4 have been observed in the lesional skin of atopic 
dermatitis patients (Fogh et al., 1989), and LTB4 has been shown to trigger acute 
scratching behaviors (Andoh and Kuraishi, 1998).  Studies also indicate that application 
of LTB4 to cultured somatosensory neurons isolated from the dorsal root ganglia evokes 
increased intracellular calcium (Andoh and Kuraishi, 2005). I was able to use LTB4 
application to evoke calcium transients in cultured somatosensory neurons from the 
dorsal root ganglia, but intriguingly, I needed to use a very high concentration of LTB4 
(100 uM) to achieve these results. In contrast, LTB4 evoked increases in intracellular 
calcium levels in cultured neutrophils from bone marrow at nanomolar levels. Although 
BLT1 (the high-affinity LTB4 receptor via which LTB4 is believed to exert its effects on 
neurons) RNA has been detected at low levels in somatosensory neurons (Usoskin et 
al., 2015), some work suggests that it exerts its effects on neurons by functioning as a 
weak activator of TRPV1 rather than by acting directly on BLT1 (Hwang et al., 2000). It 
would be interesting to culture somatosensory neurons from the dorsal root ganglia of 
BLT1 and TRPV1 knock-out mice and observe the calcium transients elicited by 
application of LTB4. If the calcium transients are abolished in TPRV1, but not BLT1, 
knock-out mice, this would support the hypothesis that the calcium transients that I 
observed are a result of LTB4 is acting upon neuronal TRPV1. A role for TRPV1 in 
prostaglandin signaling would be fascinating, and could have implications for the 
development of pain management therapeutics. Our work with LTB4 in cultured neurons 
led us to examine the BLT1 knock-out animals using the MC903 mouse model of atopic 
dermatitis. We found that these mice had a deficit in scratching behaviors at day 5, but 
scratched normally at day 8. These results were somewhat puzzling, and since the 
deficit was subtle, we eventually moved on to other mechanisms by which neutrophils 
could drive itch behaviors. What role, if any, LTB4/BLT1 signaling plays in atopic 
dermatitis remains enigmatic. 
Another interesting and quite open question has to do with the mechanisms by 
which thymic stromal lympopoietin (TSLP) exerts its effects in atopic dermatitis. TSLP is 
sometimes called a “master regulator” of allergic inflammation and is known to bias the 
inflammatory response towards a Th2 type polarization (Liu, 2006). This cytokine 
signals through a heterodimeric receptor composed of the IL7Ra chain and the TSLPR 
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chain, which is unique to the TSLP response. A wide variety of immune cells, including 
T cells, dendritic cells, B cells, basophils, mast cells, and neutrophils, express the TSLP 
receptor, TSLPR (He and Geha, 2010). Our project’s focus on neutrophils has made the 
role of TSLPR signaling in these cells particularly interesting to me. A study from West 
et al. found that TSLPR signaling in neutrophils increased production of reactive oxygen 
species in the context of Staphylococcus aureus infection (West et al., 2016). 
Furthermore, TSLPR is expressed in somatosensory neurons, and application of TSLP 
to cultured dorsal root ganglia somatosensory neurons evokes calcium transients 
(Oetjen et al., 2017; Wilson et al., 2013) and sensitizes cultured neurons such that they 
display increased responses to known pruritogens (Oetjen et al., 2017). Intriguingly, it 
also evokes acute scratching behaviors in mice upon injection into the cheek (Wilson et 
al., 2013). Taken together, these studies suggest that TSLP may play a variety of roles 
in atopic dermatitis pathogenesis via actions on diverse cell types.  
 By using a TSLPR knockout mouse and the MC903 mouse model of atopic 
dermatitis, we found that TSLPR signaling was required for itch behaviors at day 12 of 
the treatment. However, we were surprised to discover that the mice still scratched 
robustly at day 8, suggesting that TSLPR signaling does not drive itch at this earlier 
timepoint. We further examined immune cell infiltration into the and found deficits in T 
cell and basophil recruitment, which (a) dovetails nicely with previous work showing that 
TSLPR signaling is required for recruitment of these cell types and (b) supports the 
conclusion that T cells and basophils are not required for itch during the early 
development of atopic dermatitis. An interesting avenue of further research would be to 
repeat these experiments using conditional knockout animals. Considering previously 
published work highlighting a role for TSLPR signaling in neurons and neutrophils and 
our own finding that neutrophils are essential for itch behaviors in atopic dermatitis, it 
would be particularly interesting to examine mice lacking the TSLPR receptor 
specifically in somatosensory neurons and neutrophils in order to determine which cell 
types are required for the deficit in scratching behaviors. Reactive oxygen species are 
known to evoke itch (Liu and Ji, 2012), and since West et. al. found that TSLPR 
signaling in neutrophils increased release of reactive oxygen species (ROS), it is 
possible that altered production of ROS contributes to the itch deficit observed in the 
TSLPR knockout animals.   
 Indeed, we observed a deficit in scratching behaviors at day 12 in both animals 
lacking TSLPR and in animals injected with a CXCR3 antagonist. We originally 
hypothesized that the CXCR3/neutrophil signaling pathway and the TSLPR signaling 
pathways were separate, with neutrophils/CXCR3 signaling being required for itch in the 
first week of the MC903 model, whereupon TSLPR signaling and the cells of the 
adaptive immune system, particularly CD4+ Th2 cells, would start to drive scratching 
behaviors. However, our observation that CXCR3 blockade at day 12 of the model also 
ablates itch behaviors suggests that the story is more complex. There may be crossover 
between these two pathways that we do not yet fully understand: perhaps the TSLPR 
pathway drives itch at later timepoints in part by stimulating the release of cytokines 
from immune cells and/or neurons that then evoke CXCL10 release from keratinocytes.  
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 Our neutrophil depletion consistently ablated itch behaviors at day 8 of the 
MC903 model, but the precise details of the mechanism by which neutrophils drive itch 
has remained somewhat elusive. Our data suggest that CXCL10 signaling via the 
CXCR3 receptor is required for itch behaviors, and we have shown by ELISA that 
neutrophil depletion with aGr1 ablates the increased production of CXCL10 normally 
observed in the skin of MC903 treated animals. However, the link between neutrophil 
recruitment and CXCL10 production is unclear. Keratinocytes, myeloid cells and 
sensory neurons have all been shown to produce CXCL10 (Flier et al., 2001; Hashimoto 
et al., 2018; Ioannidis et al., 2016; Kanda et al., 2007; Koga et al., 2008; Michalec et al., 
2002; Padovan et al., 2002; Steain et al., 2011; Tamassia et al., 2007). Do neutrophils 
drive the release of CXCL10 from keratinocytes? If so, how? The subtle phenotype that 
we observed in the BLT1 KO animals, mentioned earlier in this chapter, has led me to 
believe that LTB4/BLT1 signaling could be involved in driving CXCL10 release from 
keratinocytes. The lack of a more dramatic phenotype in these animals, though, 
suggests that other pathways are also important. It would be interesting to measure 
CXCL10 release using an ELISA in the BLT1 KO animals at days 5 and 8 of MC903 
treatment to determine whether or not CXCL10 production is impaired in these mice. A 
particularly fascinating outcome would be impaired CXCL10 production at day 5, but not 
day 8, of MC903 treatment, which would mirror the subtle itch deficit that we observed. 
An important caveat with this experiment is that while expression of CXCL10 as 
measured by RNA Seq was slightly increased at day 5, it was not statistically significant. 
This would likely make ascertaining differences in CXCL10 protein at day 5 of MC903 
treatment between wild-type and BLT1 KO mice challenging.   
 Finally, I have been curious for a couple of years now as to what the CD4+ T cell 
polarization looks like in the context of the MC903 atopic dermatitis model. This is an 
aspect of the model that we have discussed frequently in the lab, but I have not been 
able to conduct the necessary experiments to address the question due to time 
constraints. It was long believed that atopic dermatitis was a strongly Th2 polarized 
disease, and while this is the case for many patients, the story has turned out to be 
quite a bit more nuanced. Research has now shown that many patients exhibit a mixed 
Th1/Th2 polarization, with some patients additionally having contributions from Th17 
and/or Th22 cells. These differences seem to stem partly from differences in age and 
ethnic background: young patients and Asian patients tend to exhibit more of a Th17 
type response than do adult European patients (Guttman-Yassky and Krueger, 2017). 
With this in mind, I am particularly interested to know what the polarization of the CD4+ 
T cells in the MC903 model is, because it would give us a sense of what ‘type’ of atopic 
dermatitis we are modeling. I also suspect that this polarization might change in the 
neutrophil depleted animals: I found that CD4+ T cells still infiltrate the skin at days 5 
and 8 of MC903 treatment in mice lacking neutrophils, but was not able to investigate 
their polarization. A very small amount of preliminary data suggests that depletion of 
neutrophils on days 0 – 7 of treatment ablates itch behaviors at day 12, even though 
neutrophils begin to rebound in the blood by day 8 of our depletion protocol. If these 
preliminary data were repeated, they would support the hypothesis that the neutrophils 
may be required early on in the model to ‘set up’ the chronic inflammation that drives 
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scratching in the second week of the model, and I wonder if this could be related to 
CD4+ T cell polarization.  
 The questions I raise in the preceding pages outline just a few of the potential 
experiments that could conceivably be pursued as a follow-up to the work that my co-
authors and I completed. It has been a privilege to be part of such a complex and far-
reaching project and to do research alongside an incredibly talented group of people. I 
am deeply grateful to everyone involved.  
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